

Guidelines for best practices in monitoring established coeliac disease in adult patients

Luca Elli¹✉, Daniel Leffler², Christophe Cellier³, Benjamin Lebwohl⁴, Carolina Ciacci⁵, Michael Schumann⁶, Knut E. A. Lundin^{7,8}, Stefania Chetcuti Zammit⁹, Reena Sidhu¹⁰, Leda Roncoroni^{1,11}, Julio C. Bai¹², Anne R. Lee⁴, Melinda Dennis², Marie E. Robert¹³, Kamran Rostami¹⁴, Sherine Khater³, Isabel Comino¹⁵, Angel Cebolla¹⁶, Federica Branchi⁶, Elena F. Verdu¹⁷, Juan Pablo Stefanolo¹², Randi Wolf¹⁸, Sheba Bergman-Golden¹⁸, Nick Trott¹⁰, Luigia Scudeller¹⁹, Fabiana Zingone^{20,21}, Lucia Scaramella¹ & David S. Sanders¹⁰

Abstract

Coeliac disease (CeD) is an immunological disease triggered by the consumption of gluten contained in food in individuals with a genetic predisposition. Diagnosis is based on the presence of small bowel mucosal atrophy and circulating autoantibodies (anti-type 2 transglutaminase antibodies). After diagnosis, patients follow a strict, life-long gluten-free diet. Although the criteria for diagnosis of this disease are well defined, the monitoring phase has been studied less and there is a lack of specific guidelines for this phase. To develop a set of clinical guidelines for CeD monitoring, we followed the Grading of Recommendations Assessment, Development and Evaluation methodology. Statements and recommendations with the level of evidence were developed and approved by the working group, which comprised gastroenterologists, pathologists, dieticians and biostatisticians. The proposed guidelines, endorsed by the North American and European coeliac disease scientific societies, make recommendations for best practices in monitoring patients with CeD based on the available evidence. The evidence level is low for many topics, suggesting that further research in specific aspects of CeD would be valuable. In conclusion, the present guidelines support clinicians in improving CeD treatment and follow-up and highlight novel issues that should be considered in future studies.

Sections

Introduction

Methods

Biomarkers and investigations used to monitor coeliac disease

Blood tests

Evaluation of gluten-free diet adherence and quality

Endoscopy and histology

Molecular analysis of duodenal biopsy samples in refractory CeD

Other investigations

Conclusions

A full list of affiliations appears at the end of the paper. ✉e-mail: Luca.elli@policlinico.mi.it

Evidence-based guidelines

Introduction

Coeliac disease

Coeliac disease (CeD) is an immunological disorder induced by gluten ingestion in individuals with genetic susceptibility, characterized by villous atrophy, intra-epithelial lymphocytosis and crypt hyperplasia of the small bowel. It is a chronic inflammatory state that improves when gluten-containing foods are excluded from the diet (gluten-free diet, GFD)^{1,2}. The disease primarily affects the small bowel; however, the clinical manifestations are broad, comprising both intestinal and extra-intestinal symptoms³. CeD is more frequently diagnosed in women than in men (ratio 2:1), and it is one of the most common causes of chronic malabsorption, with a worldwide prevalence of around 1%⁴.

Gluten is a storage protein of the cereal grains wheat, rye and barley⁵. It is enriched in glutamines and prolines and, as a result, is incompletely digested by gastric, pancreatic and brush border peptidases, leaving large peptides⁶. In the small intestine, these peptides trigger an autoimmune reaction involving type 2 transglutaminase (TG2), the predominant autoantigen of CeD⁷. Deamidation increases the immunogenicity of gliadin fractions (the alcohol-soluble part of gluten with immunodominant properties), facilitating binding to HLA-DQ2 or HLA-DQ8 molecules. Gliadin peptides are then presented to T cells, and this leads to the formation of anti-type 2 transglutaminase antibodies (TG2Ab), pro-inflammatory cytokines, lymphocyte infiltration and subsequent tissue injury, leading to crypt hyperplasia and villous atrophy⁸.

Diagnosis of CeD in adulthood is based on serology (TG2Ab) and duodenal biopsy while the patient is on a gluten-containing diet. Analysis of TG2Ab serum levels should be done as a first-line screening test and has high sensitivity (93%) and specificity (98%)⁹; serum analysis of anti-endomysial antibodies (EMAs) is a second-line test with high specificity; although HLA typing is usually performed in uncertain cases^{1,10}. CeD is highly correlated with the presence of HLA-DQ2 and/or HLA-DQ8 molecules. Nearly 100% of individuals diagnosed with CeD exhibit this specific genetic profile. Consequently, in cases for which the diagnosis of CeD is uncertain, HLA typing has a crucial role in ruling out the condition when the results are negative¹. Currently, to make a definitive diagnosis of CeD in adults, evidence of compatible small bowel damage is required, and, therefore, an endoscopy with multiple bulb and distal duodenal biopsies must be performed. Histologically, evaluating the villous to crypt cell ratio in well-oriented biopsy specimens is crucial: it reduces misdiagnosis, whereas Marsh and Marsh–Oberhuber score systems are currently applied to describe the CeD-related small bowel lesion and endorsed by most CeD guidelines^{11,12}. Originally, Marsh score described the small bowel damage as type 0 (normal mucosa), type 1 (presenting increased number of intra-epithelial lymphocytes, IELs), type 2 (increased IELs and crypt hyperplasia), type 3 (with villous atrophy) and type 4 (completely flattened and hypoplastic mucosa)¹². Subsequently, Oberhuber further classified the Marsh 3 lesion into distinct subtypes based on the severity of villous atrophy: 3a for mild, 3b for moderate and 3c for severe¹¹. Thus, the presence of TG2Ab in the serum and duodenal histological alterations usually make the diagnosis straightforward, and this diagnostic algorithm is supported by guidelines from various scientific societies, thereby supporting clinicians in CeD diagnosis^{1,4,10,13,14}.

Currently, the only treatment for CeD is adherence to a life-long GFD; however, it is still unclear how to monitor patients with established CeD in the most appropriate way. Moreover, the therapeutic objectives of the GFD should be systematically addressed according

to a temporal schedule, commencing with the resolution of symptoms, followed by achieving serological and mucosal normalization and ultimately, the prevention of comorbidities. Questions that require informed answers include the following. Which is the primary end point of the GFD? How should CeD activity be assessed? Is serology adequate for follow-up? Is the evaluation of small bowel mucosa necessary during the follow-up period, and at which time intervals? How should GFD adherence be measured? Currently, answers to these and other related questions are not always clear. Despite the paucity of evidence, it is common to use the same biomarkers as used for diagnosis (TG2Ab serology and duodenal histology) to monitor CeD activity and response to a GFD; furthermore, blood tests to evaluate intestinal function and the presence of common CeD comorbidities are routinely used in monitoring, often on a yearly basis. Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, we attempted to address these gaps and provide guidance to clinicians regarding a standardized and consensual approach to monitor CeD.

Scope and context

CeD is one of the most frequent immunological diseases. It is suggested that 1% of the global population could be affected by CeD^{6,15,16}. Improvement in diagnostic tools and health-care systems in low-income countries, the possibility of making a diagnosis without duodenal biopsies in children¹⁷ and diet westernization in Asia are all factors that contribute to increases in the global CeD population.

The rapidly growing CeD population and the clear gaps in the current care of patients with CeD suggest the need to develop guidelines for CeD monitoring. Studies have revealed substantial variability in monitoring practices across different countries, highlighting a lack of consistent follow-up for patients with CeD^{18,19}.

The present guidelines aim to analyse the best practices in monitoring CeD and patient response to a GFD and, therefore, provide a set of practical guidelines for clinicians using the GRADE methodology.

Methods

In October 2021, an independent guideline development group (GDG) was formed to compile best practices for the monitoring of CeD. The core group comprises dietitians, pathologists, gastroenterologists, endoscopists and methodologists, all experts in CeD and the GFD. Conflict of interest statements were collected from all panel members before and after the development of the present guidelines, and authors with specific conflicts of interest were excluded from voting. The guideline methodologist had no conflicts of interest. Notably, none of the GDG members received fees or funding for developing the present guidelines. Owing to the worldwide dispersion of the GDG, to maintain a sustainable profile, regular web calls were organized and a dedicated virtual space containing all the guideline-related material was available for all panel members^{20,21}. The panel members addressed the specific tasks and clinical questions during the first call in November 2021 (Supplementary File 1). Subgroups formed by two or three experts were assigned the various tasks and questions. Key questions were developed following a format to outline the specific patient population, intervention, comparator and outcomes (PICO format), with subsequent voting to reach an agreement on the precise formulation²². An extensive literature search using search engines that include PubMed and Embase was conducted for English-written articles with appropriate medical subject heading (MeSH) terms (Supplementary File 1). Particular attention was given to the presence

Evidence-based guidelines

of meta-analyses on dedicated web pages (Cochrane). The levels of certainty of the evidence and strength of the recommendations were defined for every part of the statement, according to the GRADE system using [GRADEpro](#)²³. All summaries of evidence for each PICO question, including research strategy and MeSH terms, answers to the questions and tables showing the studies analysed, are reported in Supplementary File 1. To define the strength of each recommendation, a 12-item decisional framework was administered to all GDG members who voted independently²⁴. During the last call in January 2023, the panel agreed on the final recommendations (consensus was defined as 70% agreement with <15% disagreement), and a representative of patients provided comments on the manuscript (Supplementary File 2). The Society for the Study of Coeliac Disease and the European Society for the Study of Coeliac Disease executive committees reviewed and endorsed this guideline.

Biomarkers and investigations used to monitor coeliac disease

Despite the absence of guidelines, clinical evaluations and varied investigations are routinely performed for CeD monitoring. GFD is expected to reduce symptoms and normalize biomarkers that were abnormal at diagnosis. Several scores are used in the diagnosis and monitoring of symptoms of gastrointestinal diseases, such as the Crohn's disease activity index²⁵, the gastro-oesophageal reflux disease impact scale²⁶ and the gastrointestinal symptom rating scale (GSRs)²⁷. These scores enable clinicians to compare patients' progress and objectively assess outcomes. GSRs²⁸ has often been used in CeD and contains five domains: abdominal discomfort, diarrhoea, indigestion, constipation and reflux. However, owing to the limitations of existing symptom scores (nonspecific and limited number of scored symptoms), a CeD-specific symptom index has been developed. The Coeliac Symptom Index is a specific tool to measure and monitor CeD-related symptoms²⁹. Together with clinical evaluation, various serological, endoscopic and histological markers are routinely used to monitor CeD and compliance with the GFD¹. These biomarkers are based on common changes seen at diagnosis (increase in TG2Ab serum levels; endoscopic markers, such as scalloping or mosaic appearance; villous atrophy on biopsy samples; and vitamin deficiencies as a consequence of malabsorption) – consequently, normalization of these biomarkers is expected when CeD is in remission. However, clinical studies suggest that these tests might not be as accurate as commonly presumed in the evaluation of CeD activity³⁰. Furthermore, the interval between each follow-up visit is largely unknown and not systematically investigated. Currently, it is suggested that patients be monitored on a yearly basis, but intervals can be shortened in the case of non-responsive CeD¹.

In the next paragraphs and in the present guideline, we evaluate the clinical utility of the various available tests and biomarkers and provide related recommendations.

Blood tests

Blood tests are widely used to monitor chronic diseases owing to their non-invasive nature. In CeD, TG2Abs are usually used to evaluate disease activity and response to the GFD¹³. However, evidence differs regarding the correlation with CeD mucosal activity³¹ and the quantity of gluten required to be ingested before titres become positive³². Additional blood tests can be performed yearly, together with TG2Ab assessment, to evaluate the nutritional state of patients and the presence of comorbidities^{10,14}.

Role of serological antibodies in prediction of adherence to the gluten-free diet

- Recommendation 1. We recommend routine serological assessment with anti-TG2 IgA serum levels in patients with CeD on a GFD; a positive value suggests poor dietary adherence or gluten contamination, whereas a negative value cannot confirm strict adherence or lack of gluten exposure.
- Level of evidence very low; strong recommendation.

CeD-specific antibodies start to decline within months of the introduction of the GFD, dropping rapidly during the first year and eventually falling to normal levels in most patients^{33–36}. Persistently positive, or not decreasing, anti-TG2 IgA levels are strongly predictive of some degree of gluten intake (poor adherence or contamination)^{33,34,37,38}. On the other hand, the sensitivity of anti-TG2 IgA for the detection of diet transgressions evaluated by patient self-reports or dietician-led assessments was as low as 52–57% in two cohort studies (53 and 95 patients, respectively)^{34,37}. This makes coeliac serology a poor negative predictor of dietary adherence, illustrating that negative anti-TG2 IgA levels should not be considered a marker of strict dietary compliance.

EMA IgA and anti-deamidated gluten peptide (DGP) IgA perform similarly to anti-TG2Ab IgA detection in this setting^{33,37}, with DGP IgA showing a tendency to lower sensitivity and EMA to higher specificity³³.

With regard to patients with CeD with IgA deficiency, anti-TG2 IgG (often detected at CeD diagnosis in these patients) levels also decline over time on a GFD but fail to reach normalization in up to 80% of cases despite long-term strict diet adherence^{39,40}. Serial measurements to assess the dynamics of anti-TG2 IgG levels might help to evaluate dietary compliance in CeD with IgA deficiency; however, data on this topic are scarce.

Overall, serology alone is not an accurate diagnostic tool for the assessment of dietary adherence in CeD. We still recommend routine serology assessments with anti-TG2 IgA in patients with CeD on a GFD. Positive anti-TG2 IgA detection levels are suggestive of poor diet adherence or gluten contamination, whereas negative anti-TG2 IgA detection cannot confirm strict adherence. In patients with IgA deficiency, anti-TG2 IgG levels tend to decline but often remain positive despite a strict GFD and should, therefore, not be used to assess adherence.

Role of serological antibodies to predict mucosal atrophy

- Recommendation 2. We do not recommend normalization of serology (anti-TG2 IgA) as a marker of mucosal recovery during a long-term GFD owing to poor sensitivity for the identification of persistent villous atrophy.
- Level of evidence very low; strong recommendation.

A meta-analysis of mostly prospective cohort studies showed that anti-TG2 IgA serology has relatively high specificity (0.83, 95% confidence interval (CI) 0.79–0.87) for CeD diagnosis but low sensitivity (0.50, 95% CI 0.41–0.60) for the identification of patients with persistent villous atrophy⁴¹. EMA IgA serology has a similar performance, with specificity 0.91 (95% CI 0.87–0.94) and sensitivity 0.45 (95% CI 0.34–0.57)⁴¹. A prospective study that involved 368 patients that aimed to assess the performance of bulbar histology for the detection of persistent villous atrophy confirmed the poor discriminatory ability of serological testing, with 39.7% sensitivity and 94.2% specificity for anti-TG2 IgA and 38.1% sensitivity and 96.4% specificity for EMA IgA⁴². Similar results were found in another study with 97 patients involved

Evidence-based guidelines

in evaluating the performance of faecal gluten immunogenic peptides and serum antibodies: anti-TG2 IgA serum analysis had 11.8–30% sensitivity and 100–72.7% specificity (depending on which of the two evaluated assays was considered) for the detection of residual mucosal damage, defined as Marsh 1 or higher⁴³. In view of these data, coeliac serology can be considered a poor predictor of persistent mucosal damage because it misses most cases of villous flattening. Some studies have proposed the modification of the cut-offs normally used for the diagnosis of CeD in an effort to improve the performance of serological assays in CeD follow-up; however, this has resulted in little or no improvement in sensitivity^{44,45}.

Although endoscopic biopsy remains the reference standard for the assessment of persistent villous atrophy at follow-up, there is a need for better non-invasive markers of intestinal damage⁴⁶. With regard to serology, DGP IgG antibodies showed good discriminatory ability for the detection of persistent villous atrophy (87% sensitivity and 89% specificity) in a single study with 60 participants, even displaying a correlation between antibody titres and the severity of mucosal damage⁴⁷. Another study, which involved 217 patients and aimed to assess the performance of a DGP IgA–IgG-based point-of-care test (POCT), demonstrated a higher sensitivity of the DGP-POCT compared with anti-TG2 IgA and EMA IgA assays for the detection of villous atrophy at follow-up (67.1% versus 44.7% and 37.7%)⁴⁸, corroborating the possible role of DGP-based assessments as surrogate markers of mucosal damage.

Anti-TG2 IgA (and EMA) antibodies should not be routinely used as a marker of mucosal recovery during a long-term GFD owing to their poor sensitivity for the identification of persistent villous atrophy. DGP-based serological assays might prove to be a better predictor of persistent villous atrophy; however, further studies are needed to explore this possibility.

Blood biochemistry

- Recommendation 3. We recommend the use of clinical chemistry analysis of blood count, iron, folate and other micronutrients for the evaluation of malabsorption and nutritional status in patients with CeD on a GFD.
- Level of evidence very low; strong recommendation.

A strict GFD can restore intestinal villi and absorption function in patients with CeD². However, studies demonstrate that mucosal recovery is not achieved in all patients, even in the absence of symptoms^{49,50} and normalization of coeliac-related antibody titres⁴¹. Therefore, laboratory tests should be used to detect nutritional deficiencies, as the nutritional parameters of patients with CeD on an optimized GFD should be comparable to those of the general population^{51,52}.

Full blood count and iron status. Studies of the effect of GFD on recovery from iron deficiency anaemia (IDA) are scarce. In most cases, recovery from anaemia usually occurs within 1 year after commencement of a strict GFD, even without additional iron supplementation^{53,54}. However, some patients with CeD continue to show IDA despite careful adherence to a GFD. A Finnish study showed that 6% of the 163 patients with CeD involved still had IDA after a 1-year GFD, especially in women⁵³. A study from Saudi Arabia showed that nutrient intake in 51 women with CeD was below the recommended dietary intake. However, blood parameter values in women with CeD who followed a GFD for longer than 1 year were comparable to those in healthy controls⁵². Another study demonstrated that in a population of 163 adults with CeD, those with IDA at diagnosis had more gastrointestinal symptoms, worse

indicators of well-being and increased levels of serum TG2Ab. After a 1-year GFD, the mucosal villous to crypt ratio was significantly lower in the anaemia group ($P = 0.008$), indicating a slower response^{53,55,56}. Scricciolo and colleagues⁵⁷ performed a clinical trial comparing 22 women with CeD on a GFD and with iron deficiency who were given either an iron-rich diet or iron supplementation. The investigators showed that the women on iron supplementation had an increase in ferritin serum levels compared with those on an iron-rich diet.

These results suggest that haemoglobin and ferritin serum levels should be monitored during follow-up, and iron supplementation should be considered when the GFD alone does not improve iron deficiency. Thus, careful monitoring of iron status is recommended in CeD follow-up, particularly in women who are in premenopause.

Lipids. Ballester-Fernández and colleagues⁵⁸ described no difference in blood levels of cholesterol and triglycerides in 64 patients with CeD compared with 74 healthy volunteers. Conversely, Remes-Troche and colleagues⁵⁹ described lower levels of those lipids compared with healthy controls and individuals without coeliac disease but with non-coeliac gluten sensitivity. However, other studies described an increased risk of abnormal serum lipid levels in patients with CeD on a GFD^{60–62}, particularly for triglycerides^{63,64}. Independently of serum lipid levels, several reports have described an increased risk of fatty liver (also known as steatotic liver⁶⁵) and metabolic dysfunction-associated fatty liver disease, which could predispose to a higher cardiovascular risk in patients with CeD on a GFD^{59,60,63,64}. Reilly and colleagues⁶⁶ showed that 29,096 individuals with CeD are at increased risk of nonalcoholic fatty liver disease (also known as metabolic dysfunction-associated steatotic liver disease⁶⁵) compared with the general population (144,522 reference individuals), particularly during the first year after CeD diagnosis, but persisting through 15 years beyond diagnosis with CeD. Liver damage should be detected through evaluation of liver serum transaminases during follow-up. Interestingly, a UK study described that in 469,095 adults, the 2,083 persons affected with CeD, aged 40–69 years, had a lower prevalence of traditional cardiovascular risk factors but a higher risk of developing cardiovascular disease than those without CeD⁶⁷. Moreover, a study from the Swedish register has shown that in a cohort of 49,829 individuals with CeD, there was an increased risk of death from cardiovascular disease compared with the general population (3.5 versus 3.4 per 1,000 person-years; hazard ratio (HR), 1.08 (95% CI 1.02–1.13))⁶⁸. In conclusion, patients with CeD should be assessed for metabolic features, such as glucose, lipid status serum biomarkers and serum liver enzymes over time, according to age and risk factors, as per the general population.

Vitamins. There are few studies investigating serum vitamin levels, with the exception of vitamin D, and data are scant with discordant results, therefore, no clear recommendations can be derived^{58,61,69–71}. Reasonably, follow-up testing should be adapted based on vitamin levels at diagnosis, and supplementation is suggested when needed.

Conversely, studies on vitamin D are numerous, and the data show that, despite deficiency at diagnosis and follow-up, there is no relationship with bone density^{58,70,72,73}. The studies, however, have several limitations, including seasonal vitamin D (sun exposure), inconsistent testing for the active form of vitamin D (also known as 1,25-dihydroxy-cholecalciferol or calcitriol), history of previous vitamin D supplementation and limited data on men. Therefore, monitoring for vitamin D should be considered based on serum levels found at diagnosis and the lifestyle of patients.

Evidence-based guidelines

Hallert and colleagues⁷⁴ reported that in a group of 30 adult patients with CeD on a GFD for several years, half of them showed low serum levels of folate, vitamin B₆ and vitamin B₁₂, associated with higher homocysteine levels. The researchers also reported lower folate and vitamin B₁₂ intake than the control group.

Fasting glucose. Despite the small size of the published studies, a strict GFD in children and/or adults with type 1 diabetes has positive effects on glycaemic control, indicating a trend towards a decrease in hypoglycaemic episodes and better glycaemic control^{62,75}. Ludvigsson and colleagues⁷⁶ described that in 9,243 individuals with CeD diagnosed before 20 years of age, CeD was associated with a 2.4-fold increased risk of later type 1 diabetes (95% CI 1.9–3.0). Conversely, the association between CeD, GFD and the development of type 2 diabetes is inconsistent. Ballester-Fernández and colleagues⁵⁸ described no variation of glucose on a GFD. Some studies reported that patients with CeD are less likely to develop type 2 diabetes and others correlate the use of a highly processed GFD with an increased risk of elevated glucose serum levels^{61,63,64}. Zanini and colleagues⁶¹ showed no change in insulin resistance in either men or women with CeD, and the mean (\pm s.d.) value for the whole cohort was 1.3 ± 0.7 at baseline and 1.3 ± 0.8 during GFD ($n = 100$).

In the context of the risk of metabolic syndrome reported earlier, patients should routinely be assessed for serum glucose levels.

Electrolytes. Ballester-Fernández and colleagues⁵⁸ reported no deficiency in zinc, copper, selenium or magnesium. There are no studies about serum levels of micronutrients, such as zinc and copper, in adult patients with CeD on a GFD. A study analysed the nutritional indices collected in persons with CeD in the cross-sectional National Health and Nutrition Examination Survey, 2009–2014. The study, which involved 16,966 participants with 28 subjects with CeD, reported that in the US population over 6 years, the zinc and copper levels of people diagnosed with CeD were similar to those of individuals without CeD despite reduced total calories and macronutrient intake⁷⁷. Rawal and colleagues⁷⁸ described that zinc plasma levels rose in 134 patients on a GFD regardless of supplementation, and Ciacci and colleagues⁷² found no differences in serum levels of phosphorus among 50 untreated and 55 treated patients with CeD. Therefore, no recommendation is possible regarding the testing of electrolytes in CeD monitoring.

Other blood biomarkers

Novel and non-routine blood tests have been used in CeD to monitor its activity and GFD adherence. Patients with the most abnormal pathology have a loss of duodenal villi cytochrome P450 3A4 (CYP3A4), a drug-metabolizing enzyme that inactivates many drugs^{79,80}. Chretien and colleagues⁸¹ conducted a clinical trial with 115 participants (47 patients with CeD, 68 healthy individuals), that showed an increase in serum concentrations of the antihypertensive drug felodipine in patients with CeD, probably secondary to decreased small intestinal CYP3A4 expression. Similar results were found for evaluation of the metabolism of the cholesterol-lowering medication simvastatin in a clinical trial with 54 participants (11 healthy volunteers, 43 patients with CeD)⁸². Furthermore, in recent years, clinical studies^{83–85} have been performed to evaluate the potential of tetramer-based assays to monitor patients with CeD on a GFD, particularly testing their expression after a gluten challenge. Other studies showed an increased level of reactive oxygen species in the serum of non-responsive patients with

CeD⁸⁶. Furthermore, *in vivo* experimental findings have indicated that citrulline, zonulin and intestinal-fatty acid binding protein (all markers of enterocyte damage) might be useful in monitoring CeD⁸⁷. However, none of them is used in current clinical practice. In the future, those novel markers that measure direct mucosal damage might complement the traditional tests. The evaluation of T cells in blood has been considered a tool for CeD detection after a short-term gluten challenge in patients on a GFD without a clear diagnosis. Evaluation of T cell features in blood could be considered during follow-up to evaluate dietary compliance^{88,89}. However, the role of these approaches outside of serology has not been fully explored.

Evaluation of gluten-free diet adherence and quality

Nutritional interviews and alimentary diaries to evaluate GFD adherence

- Recommendation 4. We recommend the use of dietetic evaluation to assess patient adherence to the GFD.
- Level of evidence low; strong recommendation.

International guidelines for the diagnosis of CeD highlight the importance of early referral to dietitians or nutritionists who have clinical experience in CeD^{14,90,91}. Their role at diagnosis includes nutritional, anthropometric (BMI, waist circumference) and psychosocial assessments, as well as delivering comprehensive dietary education to facilitate a transition to a strict life-long GFD. Regular follow-ups with dietitians or nutritionists are recommended to review the above parameters. Additionally, a central component of this follow-up is the evaluation of patient adherence to the GFD⁹².

However, there is a limited range of published data assessing the efficacy of nutritional evaluations in relation to GFD adherence in adult patients with CeD. Based on the included studies, dietetic assessments might fail to identify ongoing villous atrophy in many patients^{93–95}. Only two studies were identified that compared dietetic assessments with duodenal biopsy samples, the reference standard for assessment of disease activity. One study (in 94 patients with ongoing villous atrophy) indicated that dietitians were able to identify sources of gluten inclusion in 50% of cases, resulting in the restoration of villous height⁹⁵. The other study, which used a dichotomous outcome of 'good or poor' GFD adherence, indicated that dietitian evaluation had a sensitivity and specificity of 64% and 80%, respectively, when predicting persisting villous atrophy in a subset of 25 patients⁹⁶. There is great variation in how nutritional assessments are undertaken, and standardized nutritional assessments (SNAs) seem to be important to maximize the accuracy of evaluations⁹⁷. SNAs performed better than an adherence questionnaire (Coeliac Dietary Adherence Test (CDAT)) in one prospective cohort study conducted on 92 patients with CeD⁹⁸. Equally, another study that compared five measures of GFD adherence indicated that SNAs could not be replaced with serological markers or patient self-assessments of adherence⁹⁹. However, the current published studies on SNAs have been carried out only in Western countries, although many aspects of SNAs might be broadly generalizable across cultures; therefore, further research is required to understand the nuances of nutritional assessment of GFD adherence in different countries¹⁰⁰.

Overall, the current published literature suggests that dietetic and nutritional evaluations of GFD adherence should be standardized and, ideally, used in combination with other non-invasive methods of GFD adherence. However, the gold standard for predicting persisting villous atrophy remains the repeat duodenal biopsy.

Evidence-based guidelines

Nutritional interviews and alimentary diaries to evaluate GFD nutritional quality

- Recommendation 5. We recommend a dietetic evaluation to monitor the nutritional balance of the GFD during follow-up.
- Level of evidence very low; weak recommendation.

Several studies in adult and paediatric populations have focused on the nutritional quality of a GFD, showing that in patients with CeD, there is a reduction in the intake of fibre, iron, calcium, magnesium and B vitamins, although there was higher consumption of fatty foods, sugary foods and drinks. In addition, there was higher consumption of processed foods that would appear to have a higher glycaemic index than conventional products^{101–108}.

Although there were conflicting findings about changes in anthropometric measurements in patients with CeD compared with healthy individuals, the approach to a GFD involves changes in eating habits, such as increasing the frequency of snack and sweets consumption or eating from the pot or in inappropriate places such as the bedroom or living room¹⁰⁹. These changes, in particular, turn out to be less healthy and seem to be acquired by the patient's entire family, potentially contributing to the so-called obesogenic environment^{109,110}.

Thus, it is essential to educate care-givers on a healthy diet and lifestyle, with the final goal of ensuring correct diet instructions¹¹¹.

Meal patterns for patients with CeD should ideally be individualized, reflecting their relevant medical history, food preferences, socioeconomic status and, when applicable, an individual's risk of food insecurity (which can reduce the patient's adherence to the GFD). Individualized nutritional approaches can also promote dietary patterns that support optimal health outcomes¹¹².

The inclusion of alternative gluten-free grains such as buckwheat, amaranth, quinoa, millet and sorghum increased the nutritional profile of the GFD in patients with CeD, restricting their carbohydrate sources of rice, potatoes and corn¹¹³. Gluten-free grains can be consumed as whole grains and/or can be used to cook home-made gluten-free bread, cake, biscuits and pizza. They are important alternative pseudo-cereals that are rich in proteins, fibre, unsaturated fat, B-complex vitamins and minerals. Their intake can improve nutritional status and well-being¹⁰².

Moreover, foods that should be consumed every day are ideally home-made, natural, gluten-free preparations, which might include extra-virgin olive oil, milk, yoghurt (rich in natural probiotics), plant foods (vegetables, fresh fruits, legumes, nuts, herbs and spices, limiting salt) and fish (rich in omega 3), such as codfish, seabass, sardines and anchovies. Potatoes and animal foods should be consumed weekly; red meat and processed meats should be consumed less frequently, whereas white meats have fewer restrictions. Dairy products (preferably mozzarella, robiola, ricotta, goat cheese, feta) should be consumed moderately^{114,115}.

Patients following plant-based diets might require additional support and should be encouraged to include legumes, nuts, meat alternatives, gluten-free fortified non-dairy milk (preferably soya) and appropriate micronutrient supplementation, as required¹¹⁶.

Role of questionnaires to quantify GFD adherence in routine clinical assessment

- Recommendation 6. We recommend the use of a standardized patient-reported adherence questionnaire as a reasonable method of adherence assessment when an expert dietician is not readily available.
- Level of evidence very low; strong recommendation.

There is no single approach to the assessment of adherence to a GFD that has been shown to be highly accurate. Assessment of adherence to a GFD is distinct and should be differentiated from unintentional exposure to gluten on a GFD, as gluten exposure can be observed even when there is a high level of adherence. The traditional reference standard for the assessment of adherence to a GFD is an assessment by a dietician with expertise in CeD¹⁴. However, access to these clinicians is limited, and even among those with expertise, there is no standardized method of dietetic assessment, which might result in variations in reported adherence^{117–124}.

Standardized patient-reported adherence questionnaires represent a potential alternative to expert dietician assessments, particularly in situations in which access to an expert dietician is limited or when a comparison of adherence between patients is required. The available data suggest that the use of a standardized patient-reported adherence survey is superior to a patient self-report for assessing dietetic adherence as assessed by expert dieticians and, in some studies, has been predictive of ongoing enteropathy⁹⁹.

Several patient-reported adherence questionnaires have been published in the peer-reviewed literature, with the most commonly cited being the Biagi score¹²⁵ and the CDAT¹¹⁹; however, several newer scales, such as the GF-EAT, Diet-GFD and Standardized Diet Evaluation (SDE) have also been described¹²⁴. In clinical settings, the SDE has been reported to perform better than self-report assessments and serologies⁹⁷. However, the availability and feasibility of implementing an SDE by a specialist dietician is limited.

There are limited data on comparison of the scales; however, one study⁴² has suggested higher specificity for the Biagi score and a higher sensitivity score for the CDAT, with overall similar operating characteristics.

Overall, the data support the use of a standardized patient-reported adherence questionnaire as a reasonable method of adherence assessment when an expert dietician is not readily available or when a comparison of adherence between populations is required.

The development of new questionnaires and studies comparing the usefulness of various questionnaires might enable a single preferred instrument. At this time, however, we recommend clinicians choose the questionnaire that seems most relevant and appropriate for their patient population.

GFD adherence questionnaires for clinical assessment of patients with suspected ongoing CeD

- Recommendation 7. We recommend the use of adherence questionnaires as part of a holistic clinical assessment.
- Level of evidence very low; weak recommendation.

Although there are many potential causes of ongoing symptoms in individuals with CeD, gluten exposure has been reported to be common. In a study by Silvester and colleagues¹²⁴ in 222 patients with CeD, 91% of adults on a GFD reported gluten exposure less than once per month, whereas 66% reported intermittent symptoms from suspected gluten exposure. In comparison with studies of patient-reported adherence questionnaires in general coeliac populations, studies to assess the ability of questionnaires to detect gluten exposure in patients with ongoing symptoms or non-responsive disease (ongoing signs or symptoms potentially consistent with active CeD despite an attempted GFD) are limited. On the basis of the available studies, it is likely that standardized adherence questionnaires are superior to

Evidence-based guidelines

subject self-reports in assessing the likelihood of gluten exposure as the cause of ongoing symptoms in individuals with CeD⁹⁹. However, as evaluations of non-responsive CeD can be clinically challenging and can include several diet-based and non-diet-based aetiologies, adherence questionnaires should be used in this setting only as part of a holistic clinical assessment and when expert dietician support is not available.

Urinary and stool gluten immunogenic peptide detection

- Recommendation 8. We recommend the determination of GIPs in urine or stool in cases of non-responsive CeD when gluten intake is suspected.
- Level of evidence very low; strong recommendation.
- Recommendation 9. We recommend the use of GIPs to prove estimated gluten intake.
- Level of evidence very low; weak recommendation.

Determination of urine and/or faecal gluten immunogenic peptides (GIPs) is the only available direct approach for evaluation of voluntary or involuntary gluten consumption^{126,127}. Alternative indirect methods are based on the histopathological and immunological consequences of gluten consumption or subjective estimations by questions about symptoms or dietary habits¹⁴.

Most of the adult patients with CeD on follow-up with mucosal histological damage are adherent according to dietetic questionnaires, asymptomatic and seronegative. However, the stool and urine samples of this group of patients with persistent mucosal damage are mostly GIP positive (59–100%), and the relationship might increase with the amount of GIP and the frequency of positive GIP tests¹²⁸.

A discrete number of patients with CeD on follow-up consume detectable amounts of gluten (67–89% for weekly to monthly multiple testing). The levels of urinary and faecal GIPs of most of the patients who tested positive for one or both of these tests following a GFD are substantially lower than those obtained in the diagnosis¹²⁹. This reduction in gluten consumption in GIP-positive patients with CeD on follow-up is sufficient to produce negative results in serological tests and clinical symptoms and could be hidden in dietetic questionnaires. However, the continuous gluten consumption at the low–moderate level revealed by urinary GIP positivity in multiple tests or with substantial levels of faecal GIP seemed to have a predictive value for persistent duodenal mucosal damage in CeD¹²⁹. Thus, the use of GIP determinations (presumably multiple) can be used to verify the correctness of the GFD, frequently associated with the persistence of duodenal mucosal damage^{42,97,124,126–130}.

Gluten peptides in the stool and urine are produced from previous gluten ingestion: the concentrations of faecal and/or urinary GIP showed significant ($P < 0.001$) correlation with the amount of gluten ingested, but with a high window of variability likely owing to individual rates of gluten digestion and passage through the gastrointestinal tract, as well as the time of sample collection after gluten intake^{130,131}. Furthermore, the determination of urinary and/or faecal GIPs could be used to estimate the amount of ingested gluten, although the results on this issue seem conflicting, probably owing to the absence of a standardized protocol^{43,94,126,132–142}.

Methods to detect urine or stool GIPs could be limited by the amount of detectable ingested gluten, individual variability in gluten metabolism and the maximum time of detectable GIPs after ingestion of gluten (12–24 h for urine, 1–7 days for stool)¹³¹. Single faecal

or urine GIP determinations could detect daily ingestion of 50 mg of gluten in 15–50% of patients and 97–100% for unrestricted gluten intake (>5 g), as highlighted in a study by Burger and colleagues¹³⁰ on 15 patients.

The use of several faecal and/or urine samples at different days and times of the day and the development of a standardized and widely accepted protocol would substantially improve the sensitivity and accuracy of the assessment of diet compliance in patients with CeD.

Monitoring the effect of gluten avoidance on quality of life

- Recommendation 10. We recommend the promotion of GFD adherence to improve QoL beyond other clinical benefits. However, clinicians should be aware that GFD hypervigilance might diminish QoL and patients should be monitored for this as well.
- Level of evidence very low; weak recommendation.

Taking into account 18 studies (14 cross-sectional, three cohort, one case–control) that met the inclusion criteria, more than three-quarters found a positive association between the level of GFD adherence and quality of life (QoL) in adults with CeD^{43,143–159}. More specifically, in individuals with CeD, 14 (77.8%) studies suggested that higher GFD adherence was substantially associated with higher general or CeD-specific QoL^{143–148,150–157}. However, three studies^{156,158,159} found no correlation between GFD adherence and higher QoL, and one study¹⁵⁶ found extreme GFD vigilance associated with lower QoL. Most studies were conducted in populations of high socioeconomic status with relatively high GFD adherence and ‘good’ QoL at the onset. Studies ranged in size (50–7,044 participants), geographical location (USA: three^{151,156,157}; Europe: nine^{43,143,145–148,155,158,159}; Australia and New Zealand: four^{149,152–154}; Middle-East: two^{144,150}) and used validated instruments to assess GFD adherence and CeD-specific or general QoL. Findings were limited in that not all studies relied on biopsy-confirmed CeD, GFD adherence and QoL were based on self-reports and the cross-sectional nature of most of the studies did not infer causation. In addition to increased GFD adherence, other factors were associated with improved QoL (for example, increased food security, GFD knowledge, CeD-specific self-efficacy, self-compassion, autonomous motivation and fewer psychological and gastrointestinal symptoms) and warrant further study to better understand their role in monitoring and potential areas for intervention. It is important to point out that we focused only on general or CeD-specific QoL and did not consider other aspects of QoL, such as anxiety, depression and/or disordered eating patterns. Overall, the findings suggest that, in adults with CeD, monitoring to ensure GFD adherence might be important to promote improvements in QoL. However, there remains a concern that extreme GFD vigilance might diminish QoL and should also be monitored.

Endoscopy and histology

Routine use of follow-up duodenal and bulb biopsy to evaluate CeD activity

- Recommendation 11. We recommend against the use of a routine re-biopsy strategy in patients with CeD on a GFD.
- Level of evidence very low; strong recommendation.

The need for duodenal biopsies in CeD follow-up has been debated. In the case of seronegative CeD, the initial duodenal biopsy samples are essential for a correct diagnosis¹; however, additional data on follow-up

Evidence-based guidelines

biopsy samples in both seropositive and seronegative CeD revealed variability of the histological abnormalities throughout the length of the duodenum and lack of uniform response to gluten elimination, raising questions about the value of performing follow-up biopsies in CeD^{160–162}. Studies on mucosal healing after treatment with GFD have revealed that mucosal healing might be slow or incomplete in a substantial number of patients, with healing achieved in only 30% of patients in some studies and with higher recovery rates in children compared with adults.^{41,94,161–169} Challenges in comparing data between biopsy follow-up studies relate to the use of retrospective versus prospective methodology, the interobserver variation that occurs in evaluating histology using a categorical classification scheme (for example, Marsh–Oberhuber algorithm) and the lack of use of quantitative histology in some studies^{170,171}.

According to the criteria of the European Society for Paediatric Gastroenterology Hepatology and Nutrition, serology has primary importance in the diagnosis of CeD, regardless of symptoms¹⁷. A ‘no biopsy’ approach to CeD diagnosis based on high titres of TG2Ab has been widely debated as a possible diagnostic approach in a subgroup of adult populations; one study suggested that the avoidance of upper endoscopy procedures and biopsies could be achieved in about one-third of adult patients¹⁷². Although this approach is only for research purposes, establishing guidelines for obtaining a follow-up biopsy is challenging when considering these shifts in practice.

Only a few studies exist that link duodenal mucosal status on follow-up biopsy samples with prognosis, malabsorption, lymphoma risk and mortality. In these, persistent flat mucosa increases the risk of malignancy¹⁷³. Mortality risk was not increased in a large cohort of 7,648 patients¹⁷⁴ and showed a borderline increase (not statistically associated with persistent mucosal injury) in a smaller study with 381 patients¹⁷⁵. Conversely, mortality risk was slightly increased in a large Swedish study with 49,829 patients⁶⁸. Similarly, the rates of other complications, such as anaemia, malignancy and other malabsorption features, do not seem to increase in patients with persistent mucosal abnormalities compared with patients with normalized mucosa^{31,44,164,176–179}, apart from a slightly increased risk of hip fracture exclusively in the case of subtotal or total atrophy¹⁸⁰.

Current evidence suggests that the resolution of clinical symptom status is the most reliable prognostic factor in CeD, even though these clinical parameters do not reliably correlate with complete mucosal healing¹⁸¹.

In summary, there is insufficient evidence to suggest that clinical outcomes are substantially altered because of routine re-biopsy in adult patients with CeD.

Recommended timing and sampling strategy of duodenal biopsy in patients with CeD on a GFD

- Recommendation 12. We recommend 12–24 months from the beginning of the GFD as a reasonable time frame to repeat duodenal biopsy in treated patients with CeD, barring a severe clinical course for which repeat biopsy would be indicated in a shorter interval.
- Level of evidence very low; weak recommendation.
- Recommendation 13. We recommend four oriented biopsies in the second part of the duodenum, plus two oriented biopsies in the bulb, as a reasonable strategy to assess mucosal healing in patients with CeD on a GFD.
- Level of evidence very low; strong recommendation.

Currently, there are no studies that indicate the absolute necessity of follow-up biopsy as routine practice for adult patients with CeD in the absence of specific clinical indications. Specifically, follow-up biopsies are not mandatory if the patient with CeD is asymptomatic, on a GFD and has no other features that suggest increased risk of complications¹³. If a routine biopsy is performed in asymptomatic patients with CeD, most studies recommend a time interval of at least 24 months from the time of the initial biopsy to enable slow recovery, especially in adult populations^{161,182,183}. As stated in British and European guidelines^{1,14}, we propose the following recommendation for performing a biopsy during the follow-up.

Follow-up biopsies should be performed in patients with persistent symptoms despite adherence to a strict GFD; these are patients who develop additional red flag symptoms (anaemia, diarrhoea, malabsorption, weight loss) during gluten elimination and in patients with persistently positive CeD serology, despite adherence to a strict GFD, as assessed by a dietician (Box 1).

To establish the initial diagnosis of CeD, clinical guidelines recommend obtaining four biopsy samples from the second duodenum and two biopsy samples from the duodenal bulb to account for the possibility of a patchy distribution of injury⁴. Placing duodenal bulb and distal duodenal biopsy samples in separate specimen containers at diagnosis is not required but does provide information on the distribution of mucosal injury should that information be of interest. To the best of our knowledge, only one study addresses the location and number of biopsies needed to characterize the mucosal status at the time of follow-up⁴². In this study, repeat duodenal biopsies were performed in 368 patients: the inclusion of biopsy samples from the first portion of the duodenum increased the detection of persistent villous blunting by 10%. In light of this finding, and in the absence of evidence to suggest otherwise, adherence to current biopsy guidelines for diagnosis is recommended. Further, to detect patchy mucosal injury, near-focus narrow-band imaging is encouraged, and it is suggested that endoscopists obtain one biopsy specimen per pass of the forceps as a single-biopsy technique improves the yield of well-oriented duodenal biopsy specimens^{184,185}.

At microscopy, biopsy samples should be evaluated according to published best practice to ensure that only well-oriented villous–crypt units are assessed¹⁸⁶. There are data to suggest that morphometric measurements of villous height to crypt depth ratios result in better interobserver agreement on mucosal abnormalities than non-morphometric

Box 1

Indications to perform a follow-up biopsy in coeliac disease

Indications to perform a follow-up biopsy in coeliac disease following strict adherence to the gluten-free diet

- Persisting symptoms
- Development of additional red flag symptoms and/or haematinic deficiencies
- Positive serology (type 2 transglutaminase antibodies)
- Patient choice or preference

Evidence-based guidelines

approaches, and it is hoped that digital approaches to mucosal assessments will become more widely available in the future¹⁸⁷.

Molecular analysis of duodenal biopsy samples in refractory CeD

Refractory coeliac disease (RCeD) is defined by the persistence of symptoms and villous atrophy in the absence of other causes despite a strict GFD for at least 6 months¹⁸⁸. RCeD can be further classified as type I and type II on the basis of the number of aberrant IELs and clonal rearrangement of the T cell receptor (TCR)¹⁸⁹. These aberrant IELs (surface CD3⁻ and intracellular CD3⁺, surface CD8⁻) can be identified by immunohistochemistry (IHC) and, more accurately, by flow cytometry. In RCeD type II, aberrant IELs make up 20% or more of total IELs on flow cytometry and more than 50% on IHC¹⁹⁰. RCeD type II is considered a low-grade intra-epithelial lymphoma^{188,189}. Typically, RCeD should be managed in tertiary or national referral centres with specific experience in this rare form of CeD.

TCR clonality analysis and immunohistochemistry

- Recommendation 14. We recommend the use of TCR clonality analysis to subtype refractory CeD. If immunophenotyping by flow cytometry of isolated small intestinal IELs is not available, a combinatory approach of TCR clonality analysis and IHC of duodenal mucosa is recommended.
- Level of evidence very low; weak recommendation.

Eight studies were identified that included data on diagnostic accuracy for RCeD subtype I or II^{191–198}. However, none of these was designed as a prospective diagnostic study, recruiting patients affected by so-far unresolved enteropathies, including those with a prior diagnosis of CeD and following a strict, prospectively designed diagnostic trait. Furthermore, comparability of the included studies is somewhat hampered by lack of a gold standard that defines RCeD subtypes and marked differences in the purpose of these non-prospective studies that might affect the selection of patients to include a homogeneous patient population to address the respective study aims.

In particular, the sensitivity in diagnosis of RCeD type II with IHC was found to be 62–100%, whereas specificity was 70–100%¹⁹⁹. The sensitivity of TCR clonality analysis by PCR ranged from 53% to 100%, whereas the specificity range was 0–100%^{199,200}. Although these ranges document a substantial scatter of data, the somewhat more stable sensitivities in analysing the T cell clonality and the more stable specificities in the IHC analysis would favour a sequential diagnostic process. Moreover, early studies have shown that patients with evident TCR clonality (RCeD type II), who present with small intestinal IELs that are CD8⁻ or TCR $\alpha\beta$ ⁻, are more prone to develop an enteropathy-associated T cell lymphoma, which might implicate a prognostic function of this marker¹⁹⁷.

One issue in the interpretation of TCR clonality analyses is how to deal with an oligoclonal band pattern and prominent clonal peaks. Generally, most oligoclonal results should be interpreted as normal (that is, not-disease-related) findings. However, prominent clonal peaks within an oligo- or polyclonal background can be substantial, specifically when they are reproduced in independent mucosal samples of the same patient²⁰¹.

One IHC analysis that should be further observed is immunostaining for NKp46⁺ IELs of the small intestinal mucosa, as this seems to have a very good discriminatory property¹⁹¹.

Both techniques, immunophenotyping by IHC and analysis of TCR clonality, have limitations with regard to diagnostic accuracy.

Specifically, the analysis of TCR clonality by PCR of the variable domain of the TCR lacks specificity²⁰¹.

If other techniques (for example, multi-parameter testing by flow cytometry) are unavailable, performing a combination of IHC and TCR clonality testing is recommended.

Diagnostic accuracy of these techniques increases when identical prominent clonal PCR sequences are confirmed in a second independent mucosa sample that originates from an independent gastroscopy and by interpreting the two diagnostic modalities sequentially by identifying clonal T cell populations first, and second, by judging the risk of progression to lymphoma by IHC immunophenotyping of small intestinal IELs¹⁹⁷.

Role of flow cytometric analysis of isolated small intestinal intra-epithelial lymphocytes

- Recommendation 15. We recommend the use of flow cytometry to immunophenotype small intestinal IELs as the reference standard for subtype RCeD.
- Level of evidence very low; strong recommendation.

Five studies were identified that included data on diagnostic accuracy for determination of RCeD subtype by flow cytometry after immunostaining^{188,190,192,199,202}. Most studies identified the so-called aberrant lymphocyte population by immunostaining for cytoplasmic CD3⁺CD7⁺CD103⁺ lineage lymphocytes in a population of isolated, mostly IELs from small intestinal mucosa¹⁹⁰. Again, these studies were not prospectively designed. Furthermore, the comparability of the included studies was similarly hampered by the factors listed earlier^{188,192,202}.

The sensitivity for diagnosis of RCeD type II by flow cytometry was, in most studies, as high as 100%. However, these results included some studies that had not initially been designed to evaluate the diagnostic accuracy of flow cytometry^{188,202}. Nevertheless, one study found a significantly ($P = 0.0009$) reduced sensitivity for flow cytometry, which was allocated to a small number of patients (four among 30 patients with RCeD) with an unusual fate of RCeD, for example, the development of $\gamma\delta$ T cell lymphoma¹⁹⁹. This study suggested that combining TCR clonality analysis and flow cytometry results in an increased diagnostic yield. This observation¹⁹⁹ needs to be critically appraised, as some of the studies introduced in the previous paragraph described markedly decreased sensitivities for the TCR clonality analysis.

If available, immunophenotyping of isolated small intestinal IELs by flow cytometry after immunostaining should be performed for RCeD subtyping, as it has high diagnostic accuracy. The panel should comprise at least the following antibody markers: surface CD3, intracytoplasmic CD3, CD7, CD103, CD45 and, eventually, other markers, such as CD4, CD8 and TCR antibodies.

As one study identified a circumscribed lack of sensitivity of this technique¹⁹², a combinatory approach analysing small intestinal TCR clonality and immunophenotyping of small intestinal IELs by flow cytometry can be considered.

Monitoring of CeD with small bowel endoscopy

- Recommendation 16. We recommend the use of capsule endoscopy and/or device-assisted enteroscopy in CeD monitoring in cases of suspected complications and RCeD.
- Level of evidence very low; strong recommendation.

Features of CeD in the small bowel, such as villous atrophy, scalloping of folds, mosaicism, nodularity of the mucosa, fissuring of folds and ulcers,

Evidence-based guidelines

can be delineated on small bowel capsule endoscopy (SBCE)^{203–205}. The sensitivity of SBCE to delineate features of CeD varies between 70% and 93% and the specificity varies between 90% and 100%^{203,204,206–210}. However, duodenal histology remains the gold standard in making the diagnosis.

SBCE has a role in the diagnosis of CeD in which there is inadequate evidence for the diagnosis of CeD (normal or mildly positive CeD serology or evidence of Marsh 1 and 2 disease but with absence of villous flattening) or in which patients refuse or cannot undergo a gastroduodenoscopy for duodenal biopsy samples^{211–213}.

Patients with established CeD occasionally present with persistent or recurrent signs and symptoms of malabsorption. These individuals require further investigation to rule out other causes for their symptoms, including inflammatory bowel disease. Although duodenal histology helps to determine whether there is persistent disease, SBCE can have a role in assessing disease extent in the small bowel and exclude complications^{214–226}.

The length of the affected small bowel has a poor correlation with clinical symptoms and coeliac serology^{203,204,207,209,227}. These should not determine whether further investigations, including SBCE, are carried out in patients with persistent symptoms. There are only limited data that correlate symptoms and coeliac serology with a diagnostic yield of SBCE for CeD features and extent of disease^{203,221,227}.

Although SBCE has high sensitivity for the detection of macroscopic changes in CeD, there is poor correlation between the severity of duodenal histology and CeD-related findings on SBCE^{203,204,227}. Only a few studies describe a positive correlation between findings on SBCE and the severity of histology^{213,222}.

RCeD is a recognized complication of CeD. RCeD type II carries a low survival rate¹⁹³. SBCE can identify complications of RCeD that most commonly occur in the distal small bowel, such as adenocarcinoma and enteropathy-associated T cell lymphoma^{217,221,228}. Dedicated small bowel radiology has a complementary role to SBCE in the diagnosis of malignancies, in staging or in cases in which there is a high suspicion of malignancy but a negative SBCE^{194,229,230}. However, superficial ulceration, mainly occurring in the pre-malignant phase (ulcerative jejunoileitis), can be missed by radiology and is more accurately assessed on SBCE^{220,222,223,225,229}.

A histological diagnosis of malignancy can be confirmed during device-assisted enteroscopy in patients with suspected complications delineated on SBCE^{228,231–237}.

Patients with RCeD require close monitoring and regular screening with repeated duodenal histology to assess RCeD type I and type II, and repeated SBCE can be helpful in measuring the extent of the disease and ruling out complications. The interval of surveillance remains unclear^{234,235}. Patients with a complicated disease tend to have a large portion of the small bowel involved and a corresponding worse prognosis (RCeD type II versus type I versus uncomplicated CeD)²³⁶. The extent of disease (that is, the number of small bowel segments involved) can be assessed on SBCE as a measurement of response to treatment in RCeD²³⁶. Mild or no improvement in the extent of the disease can be considered an indication to alter or step up therapy²³⁷.

Other investigations

Evaluation of intestinal absorption in CeD: D-xylose breath test or urinary mannitol secretion

- Recommendation 17. We do not recommend the use of the D-xylose breath test or urinary secretion test for absorption evaluation in patients with CeD.
- Level of evidence very low; strong recommendation.

Permeability testing (D-xylose testing, lactulose to mannitol ratio) might detect changes in intestinal permeability associated with CeD; however, evidence of its use is limited and mostly dated, with a sensitivity and specificity subject to substantial variability. Therefore, these tests are not recommended during follow-up in patients with CeD^{238,239}.

Bone mineral density

One of the most common and well-documented extra-intestinal manifestations of CeD is bone disease (osteopenia and osteoporosis), which increases fracture risk²⁴⁰. Bone tissue undergoes life-long remodelling involving synthesis and resorption processes²⁴¹. Although bone health has been clinically recognized in CeD for several decades, the introduction of bone mineral density (BMD) measurement via dual-energy X-ray absorptiometry (DXA) in the late 1980s allowed the objective measurement of BMD at different body sites²⁴². Bone loss is a common finding in untreated patients with CeD, despite many of them not meeting the criteria for osteoporosis²⁴³. Although malabsorption has been causally linked to adverse bone health in CeD, current studies have shown that genetics, local and systemic immunological factors, lack of physical activity and potential microbiota abnormalities might contribute to bone deterioration^{244–247}. Indeed, osteoporosis prevalence as measured by DXA scan is affected by, among other factors, biological sex, geography, area of skeleton measured, age at disease onset and at diagnosis, clinical phenotype, menopause or andropause, and the degree of adherence to the GFD^{240,241}. Because of the multifactorial nature of osteoporosis, its worldwide prevalence in CeD ranges from 1.7% to 42%²⁴¹. According to two meta-analyses that investigated the most common clinical consequences of osteoporosis, there is a 60–100% excess of bone fractures before CeD diagnosis compared with the general population^{248,249}. Notably, after the first year of the GFD, fracture excess is comparable to that of the general population despite the fact that BMD is not normalized in most patients with osteoporosis²⁵⁰. A decrease in BMD, as measured by DXA in a patient on a GFD, might be due to poor diet adherence, the onset of menopause or andropause, or other factors related to osteoporosis, but not necessarily to CeD pathogenesis.

Although the Fracture Risk Assessment tool has been developed to estimate the 10-year probability of major osteoporotic fractures and mortality risk in the general population, there is no concrete evidence of the value of incorporating this tool in the assessment of patients with CeD. Future work will determine whether approaches such as this help in the evaluation of bone health in individuals who are undergoing a targeted GFD²⁵¹.

Impaired BMD is frequent in untreated CeD, leading to an increased risk of bone fractures²⁴¹. Delays in diagnosis are associated with severe bone deterioration²⁴⁰. Despite microstructural evidence of bone loss in most patients, including those with normal BMD²⁵², studies have shown that the deterioration of bone health is greater in patients with a classical clinical presentation than in patients with subclinical or asymptomatic CeD²⁵³. DXA can provide information about baseline BMD in patients newly diagnosed with CeD. Other surrogate markers of bone metabolism, such as serum levels of ionic calcium, serum vitamin D, bone-specific alkaline phosphatase, parathyroid hormone or surrogate markers of bone resorption (such as cross-linked C-telopeptide, C-terminal telopeptide of type I collagen, cross-linked N-telopeptide), can provide incremental information on bone metabolism²⁴⁰.

The evidence discussed earlier supports that DXA and bone metabolism markers could be useful to assess baseline bone health at diagnosis; however, experts have not reached consensus on the best time to indicate this test. An accurate diagnosis of bone health

Evidence-based guidelines


deterioration can enable interventions to delay or correct complications. On the other hand, bone health evaluation using DXA in patients with subclinical or asymptomatic CeD has not been sufficiently investigated, and no appropriate indications have been developed to date. These gaps should be addressed to improve bone health management and the prevention of complications following the initiation of a GFD.

Following the start of a GFD, BMD has been shown to improve²⁵³. This beneficial effect is associated with a reduction in bone fractures, even though this clinical event is not solely dependent on bone strength²⁵⁰. Patients with the most severe BMD baseline impairment

rarely normalize bone mineral content. Despite persistent BMD impairment, as measured by DXA, 1 year after the GFD, bone fracture risk normalizes²⁵³.

Similarly, despite the fact that BMD in patients with subclinical or asymptomatic CeD is usually impaired at baseline, the low prevalence of fractures, which was comparable in 148 patients with CeD and 296 individuals as controls, casts doubt on the need for annual DXA measurement. However, the demonstration of BMD deterioration after initiation of the GFD in such patients, which is, in most cases, secondary to dietetic transgressions²⁵⁴, can be a strong argument to improve dietetic compliance advice for adequate calcium and vitamin D intake

a Test and parameters



- To be monitored on an yearly basis with the involvement of a dietician or nutritionist expert in GFD
- To monitor and evaluate only in case of non-responsiveness to GFD, suspicion of a refractory state
- To evaluate newly diagnosed patients with CeD with an additional risk factor for low BMD, e.g. menopause

b Expected normalization timeline




Fig. 1 | Summary of the main biomarkers, clinical parameters and tests used to monitor coeliac disease activity and gluten-free diet. **a**, Here are indicated the parameters related to the gluten-free diet (GFD) monitoring, coeliac disease (CeD) activity and dual-energy X-ray absorptiometry (DXA) usually considered a consequence of prolonged malabsorption. Alterations of anti-type 2 transglutaminase antibody (TG2Ab), symptoms and blood tests during the monitoring phase could be considered the expression of both GFD

low adherence and/or residual activity of CeD. T cell receptor (TCR) clonality and duodenal flow cytometry (flow cyt) recognize and classify a refractory state, I or II. **b**, The lower panel of the figure shows that symptoms and biomarkers (such as antibodies and histology) usually recover in different time frames, with symptoms resolving more quickly than histological changes. BMD, bone mineral density; GIP, gluten immunogenic peptide; RCeD, refractory coeliac disease.

Evidence-based guidelines

Table 1 | Summary of recommendations

Recommendation	Strength	Level of evidence
Blood tests		
1. We recommend routine serological assessment with anti-TG2 IgA serum levels in patients with CeD on a GFD; a positive value suggests poor dietary adherence or gluten contamination, whereas a negative value cannot confirm strict adherence or lack of gluten exposure	Strong	Very low
2. We do not recommend normalization of serology (anti-TG2 IgA) as a marker of mucosal recovery during a long-term GFD owing to poor sensitivity for the identification of persistent villous atrophy	Strong	Very low
3. We recommend the use of clinical chemistry analysis of blood count, iron, folate and other micronutrients for the evaluation of malabsorption and nutritional status in patients with CeD on a GFD	Strong	Very low
GFD evaluation		
4. We recommend the use of dietetic evaluation to assess patient adherence to the GFD	Strong	Low
5. We recommend a dietetic evaluation to monitor the nutritional balance of the GFD during follow-up	Weak	Very low
6. We recommend the use of a standardized patient-reported adherence questionnaire as a reasonable method of adherence assessment when an expert dietician is not readily available	Strong	Very low
7. We recommend the use of adherence questionnaires as part of a holistic clinical assessment	Weak	Very low
8. We recommend the determination of GIPs in urine or stool in cases of non-responsive CeD when gluten intake is suspected	Strong	Very low
9. We recommend the use of GIPs to prove estimated gluten intake	Weak	Very low
10. We recommend the promotion of GFD adherence to improve QoL beyond other clinical benefits. However, clinicians should be aware that GFD hypervigilance might diminish the QoL, and patients should be monitored for this as well	Weak	Very low
Endoscopy and histology		
11. We recommend against the use of a routine re-biopsy strategy in patients with CeD on a GFD	Strong	Very low
12. We recommend 12–24 months from the beginning of the GFD as a reasonable time frame to repeat duodenal biopsy in treated patients with CeD, barring a severe clinical course for which repeat biopsy would be indicated in a shorter interval	Weak	Very low
13. We recommend four oriented biopsies in the second part of the duodenum, plus two oriented biopsies in the bulb, as a reasonable strategy to assess mucosal healing in patients with CeD on a GFD	Strong	Very low
14. We recommend the use of TCR clonality analysis to subtype refractory CeD. If immunophenotyping by flow cytometry of isolated small intestinal IELs is not available, a combinatory approach of TCR clonality analysis and IHC of duodenal mucosa is recommended	Weak	Very low
15. We recommend the use of flow cytometry to immunophenotype small intestinal IELs as the reference standard for subtype RCeD	Strong	Very low
16. We recommend the use of capsule endoscopy and/or device-assisted enteroscopy in CeD monitoring in cases of suspected complications and RCeD	Strong	Low
Other Investigations		
17. We do not recommend the use of the D-xylose breath test or urinary secretion test for absorption evaluation in patients with CeD	Strong	Very low

CeD, coeliac disease; GFD, gluten-free diet; GIP, gluten immunogenic peptide; IEL, intra-epithelial lymphocyte; IHC, immunohistochemistry; QoL, quality of life; RCeD, refractory coeliac disease; TCR, T cell receptor; TG2, type 2 transglutaminase.

and physical exercise, although the latter seems to have a less relevant role in ameliorating BMD in premenopausal women²⁵⁵. In some cases, and despite strict GFD adherence, bone deterioration might be related to secondary intrinsic bone disorders that are unrelated to CeD²⁴¹. Finally, menopause and andropause can affect bone mineralization and quality²⁵⁶. Thus, it seems reasonable to investigate BMD by DXA in any patient with CeD who has reached this stage of life. In the absence of scientific evidence, we suggest adherence to the accepted international guidelines on osteoporosis^{257,258}.

Conclusions

CeD is an increasingly important public health concern, given the high prevalence of the disease and the growing appreciation of the potential long-term effects of this disease on patients and the health-care system. As CeD is a life-long condition with increased risks of systemic

complications and limitations in current dietetic treatments, ongoing monitoring has been frequently recommended. However, evidence-based guidelines for monitoring practices are not available. In this article, we attempt to provide recommendations regarding the use of key monitoring assessments frequently used in current clinical practice (summarized in Fig. 1 and Table 1). In Box 2, the main concepts are briefly described.

The strengths of this work include the rigorous approach using modern GRADE methodology and the inclusion of experts in CeD from a wide range of disciplines. However, we acknowledge that the level of evidence is low. In addition, these guidelines are focused on the follow-up of adults with CeD and might not apply to paediatric populations.

Unfortunately, as a result of the systematic evaluation of the currently available research in the monitoring of patients with CeD,

Box 2

Main monitoring indications

Key points to consider during coeliac disease monitoring

- Type 2 transglutaminase antibody (TG2Ab) titres should be regularly monitored, as persistent elevation is suggestive of gluten exposure; however, the normalization of TG2Ab is not a sensitive marker of mucosal normalization.
- Nutritional testing in patients on a gluten-free diet (GFD) should be based on deficiencies observed at diagnosis, with special attention to iron, vitamin D and metabolic parameters. Thus, in the absence of risk factors and comorbidities, blood tests to routinely monitor coeliac disease (CeD) should include blood count, iron status, liver enzymes and vitamins.
- Evaluation by a specialist dietician for the assessment of GFD adherence appears to perform better than adherence questionnaires; however, combination of dietetic assessment with adherence questionnaires and gluten immunogenic peptide testing might be more accurate than dietetic assessment alone.
- Evaluation by a specialist dietician remains the gold standard for assessment of the nutritional quality of the GFD to support patients in achieving optimal micronutrient intake and macronutrient balance.
- Repeat duodenal biopsy on a GFD might not be routinely necessary; however, when performed, it should generally be 12–24 months after diagnosis.
- Video capsule endoscopy, enteroscopy and assessment of T cell receptor clonality and lymphocyte aberrance by flow cytometry should be considered in patients with ongoing or alarming symptoms, including suspicions of CeD complications.
- Bone mineral density should be considered in most adult patients after CeD diagnosis, especially when premenopausal or andropause age is approaching.

the present work underlines the lack of evidence and the need for further research in this field. The lack of research on relevant issues that form the basis of CeD monitoring is surprising. The frequency of controls is not established and is usually driven by regional organizations rather than scientific evidence. There are multiple professional figures included in the monitoring phase, but they are dependent on local resources and organizations. The dynamics of TG2Ab IgG levels to detect poor dietetic compliance in CeD with IgA deficiency is completely unknown. Furthermore, the optimal method for tissue sampling during upper endoscopy in the case of a follow-up biopsy is also completely unknown, such as the possible adoption of different grading systems at diagnosis and during follow-up²⁵⁹. In reality, the Marsh score serves as an indicator of the most severe histological lesion identified, without taking into account the percentage of mucosal involvement. However, it is important to note that mucosal involvement might still hold importance in the context of ongoing monitoring²⁵⁹. The role of bulb biopsies in follow-up is far from clear²⁶⁰. The use of GIP detection in urine and stool, included here for the first time, is becoming more and more relevant in the evaluation of GFD adherence¹⁴¹, and represents the only way to test the presence of gluten in patients' diets directly. Telemedicine emerged as a crucial tool during the coronavirus disease 2019 (COVID-19) pandemic for the continuous monitoring of various gastrointestinal diseases. Although its application for this purpose was highly desirable, its potential future integration, in conjunction with point-of-care tests, to monitor CeD and assess adherence to a GFD presents certain uncertainties²⁶¹. From this point of view, the present article represents an important instrument to drive clinical research in the next years.

In conclusion, we anticipate that this guideline will provide pragmatic information to clinicians and enable the improvement and consistency of care of patients with CeD, as well as highlight important areas for future research.

Published online: 18 December 2023

References

1. Al-Toma, A. et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. *United European Gastroenterol. J.* **7**, 583–613 (2019).
2. Elli, L. et al. Management of celiac disease in daily clinical practice. *Eur. J. Intern. Med.* **61**, 15–24 (2019).
3. Green, P. H. R., Krishnareddy, S. & Lebowitz, B. Clinical manifestations of celiac disease. *Dig. Dis.* **33**, 137–140 (2015).
4. Rubio-Tapia, A., Hill, I. D., Kelly, C. P., Calderwood, A. H. & Murray, J. A. ACG clinical guidelines: diagnosis and management of celiac disease. *Am. J. Gastroenterol.* **108**, 656–676 (2013).
5. Wieser, H. Chemistry of gluten proteins. *Food Microbiol.* **24**, 115–119 (2007).
6. Schuppan, D., Dennis, M. D. & Kelly, C. P. Celiac disease: epidemiology, pathogenesis, diagnosis, and nutritional management. *Nutr. Clin. Care* **8**, 54–69 (2005).
7. Elli, L., Bergamini, C. M., Bardella, M. T. & Schuppan, D. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. *Dig. Liver Dis.* **41**, 541–550 (2009).
8. Iversen, R. & Sollid, L. M. The immunobiology and pathogenesis of celiac disease. *Annu. Rev. Pathol.* **18**, 47–70 (2022).
9. Catassi, G. N., Pulvirenti, A., Monachesi, C., Catassi, C. & Lionetti, E. Diagnostic accuracy of IgA anti-transglutaminase and IgG anti-deamidated gliadin for diagnosis of celiac disease in children under two years of age: a systematic review and meta-analysis. *Nutrients* **14**, 7 (2021).
10. Husby, S., Murray, J. A. & Katzka, D. A. AGA clinical practice update on diagnosis and monitoring of celiac disease-changing utility of serology and histologic measures: expert review. *Gastroenterology* **156**, 885–889 (2019).
11. Oberhuber, G., Granditsch, G. & Vogelsang, H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. *Eur. J. Gastroenterol. Hepatol.* **11**, 1185–1194 (1999).
12. Marsh, M. N. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). *Gastroenterology* **102**, 330–354 (1992).
13. Zingone, F. et al. Guidelines of the Italian societies of gastroenterology on the diagnosis and management of coeliac disease and dermatitis herpetiformis. *Dig. Liver Dis.* **54**, 1304–1319 (2022).
14. Ludvigsson, J. F. et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. *Gut* **63**, 1210–1228 (2014).
15. Makharia, G. K. et al. The global burden of coeliac disease: opportunities and challenges. *Nat. Rev. Gastroenterol. Hepatol.* **19**, 313–327 (2022).
16. Singh, P. et al. Global prevalence of celiac disease: systematic review and meta-analysis. *Clin. Gastroenterol. Hepatol.* **16**, 823–836.e2 (2018).
17. Husby, S. et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition guidelines for diagnosing coeliac disease 2020. *J. Pediatr. Gastroenterol. Nutr.* **70**, 141–156 (2020).
18. Lundin, K. E. et al. Understanding celiac disease monitoring patterns and outcomes after diagnosis: a multinational, retrospective chart review study. *World J. Gastroenterol.* **27**, 2603–2614 (2021).

Evidence-based guidelines

19. Herman, M. L. et al. Patients with celiac disease are not followed up adequately. *Clin. Gastroenterol. Hepatol.* **10**, 893–899.e1 (2012).
20. Bortoluzzi, F. et al. Sustainability in gastroenterology and digestive endoscopy: position paper from the Italian Association of Hospital Gastroenterologists and Digestive Endoscopists (AIGO). *Dig. Liver Dis.* **54**, 1623–1629 (2022).
21. Rodríguez De Santiago, E. et al. Reducing the environmental footprint of gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) Position Statement. *Endoscopy* **54**, 797–826 (2022).
22. Brown, D. A review of the PubMed PICO tool: using evidence-based practice in health education. *Health Promot. Pract.* **21**, 496–498 (2020).
23. Kavanagh, B. P. The GRADE system for rating clinical guidelines. *PLoS Med.* **6**, e1000094 (2013).
24. GRADE Handbook. <https://gdt.gradepro.org/app/handbook/handbook.html#h.t16ajiafo2x> (2013).
25. Best, W. R., Bechtel, J. M. & Singleton, J. W. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). *Gastroenterology* **77**, 843–846 (1979).
26. Jones, R., Coyne, K. & Wiklund, I. The gastro-oesophageal reflux disease impact scale: a patient management tool for primary care. *Aliment. Pharmacol. Ther.* **25**, 1451–1459 (2007).
27. Revicki, D. A., Wood, M., Wiklund, I. & Crawley, J. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. *Qual. Life Res.* **7**, 75–83 (1998).
28. Lohiniemi, S., Mäki, M., Kaukinen, K., Laippala, P. & Collin, P. Gastrointestinal symptoms rating scale in coeliac disease patients on wheat starch-based gluten-free diets. *Scand. J. Gastroenterol.* **35**, 947–949 (2000).
29. Leffler, D. A. et al. A validated disease-specific symptom index for adults with celiac disease. *Clin. Gastroenterol. Hepatol.* **7**, 1328–1334 (2009).
30. Itzlinger, A., Branchi, F., Elli, L. & Schumann, M. Gluten-free diet in celiac disease—forever and for all? *Nutrients* **10**, 1796 (2018).
31. Farina, E. et al. Clinical value of tissue transglutaminase antibodies in celiac patients over a long term follow-up. *Nutrients* **13**, 3057 (2021).
32. Leffler, D. et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. *Gut* **62**, 996–1004 (2013).
33. Sugai, E. et al. Dynamics of celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment of compliance with treatment. *Dig. Liver Dis.* **42**, 352–358 (2010).
34. Nachman, F. et al. Serological tests for celiac disease as indicators of long-term compliance with the gluten-free diet. *Eur. J. Gastroenterol. Hepatol.* **23**, 473–480 (2011).
35. Zanini, B. et al. Five year time course of celiac disease serology during gluten free diet: results of a community based 'CD-Watch' program. *Dig. Liver Dis.* **42**, 865–870 (2010).
36. Bürgin-Wolff, A., Dahlbom, I., Hadziselimovic, F. & Petersson, C. J. Antibodies against human tissue transglutaminase and endomysium in diagnosing and monitoring coeliac disease. *Scand. J. Gastroenterol.* **37**, 685–691 (2002).
37. Vahedi, K. et al. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. *Am. J. Gastroenterol.* **98**, 1079–1087 (2003).
38. Dipper, C. R. et al. Anti-tissue transglutaminase antibodies in the follow-up of adult coeliac disease. *Aliment. Pharmacol. Ther.* **30**, 236–244 (2009).
39. Korponay-Szabó, I. R. et al. Elevation of IgG antibodies against tissue transglutaminase as a diagnostic tool for coeliac disease in selective IgA deficiency. *Gut* **52**, 1567–1571 (2003).
40. Cataldo, F. et al. IgG(1) antiendomysium and IgG antitissue transglutaminase (anti-tTG) antibodies in coeliac patients with selective IgA deficiency. Working Groups on Celiac Disease of SIGEP and Club del Tenue. *Gut* **47**, 366–369 (2000).
41. Silvester, J. A. et al. Tests for serum transglutaminase and endomysial antibodies do not detect most patients with celiac disease and persistent villous atrophy on gluten-free diets: a meta-analysis. *Gastroenterology* **153**, 689–701.e1 (2017).
42. Coleman, S. H. et al. What is the optimal method assessing for persistent villous atrophy in adult coeliac disease? *J. Gastrointest. Liver Dis.* **30**, 205–212 (2021).
43. Laserna-Mendieta, E. J. et al. Poor sensitivity of fecal gluten immunogenic peptides and serum antibodies to detect duodenal mucosal damage in celiac disease monitoring. *Nutrients* **13**, 98 (2020).
44. Fang, H. et al. Undetectable negative tissue transglutaminase IgA antibodies predict mucosal healing in treated coeliac disease patients. *Aliment. Pharmacol. Ther.* **46**, 681–687 (2017).
45. Packova, B. et al. Non-invasive prediction of persistent villous atrophy in celiac disease. *World J. Gastroenterol.* **26**, 3780–3791 (2020).
46. Stefanelli, G. et al. Serum transglutaminase antibodies do not always detect the persistent villous atrophy in patients with celiac disease on a gluten-free diet. *Eur. J. Gastroenterol. Hepatol.* **33**, e650–e655 (2021).
47. Spatola, B. N. et al. Persistence of elevated deamidated gliadin peptide antibodies on a gluten-free diet indicates nonresponsive coeliac disease. *Aliment. Pharmacol. Ther.* **39**, 407–417 (2014).
48. Lau, M. S. et al. The role of an IgA/IgG-deamidated gliadin peptide point-of-care test in predicting persistent villous atrophy in patients with celiac disease on a gluten-free diet. *Am. J. Gastroenterol.* **112**, 1859–1867 (2017).
49. Ciacci, C., Cavallaro, R., della Valle, N. & d'Argenio, G. The use of serum tTG-ab assay in patients on gluten-free diet as a measure of dietetic compliance. *Gastroenterology* **122**, 588 (2002).
50. Kaukinen, K. et al. Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. *Aliment. Pharmacol. Ther.* **25**, 1237–1245 (2007).
51. Burger, J. P. W. et al. Low yield for routine laboratory checks in follow-up of coeliac disease. *J. Gastrointest. Liver Dis.* **27**, 233–239 (2018).
52. Alhosain, A. I. et al. Long-term effect of gluten-free diets on nutritional status, body composition, and associated factors in adult Saudi females with celiac disease. *Nutrients* **14**, 2090 (2022).
53. Saukkonen, J. et al. Clinical characteristics and the dietary response in celiac disease patients presenting with or without anemia. *J. Clin. Gastroenterol.* **51**, 412–416 (2017).
54. Annibale, B. et al. Efficacy of gluten-free diet alone on recovery from iron deficiency anemia in adult celiac patients. *Am. J. Gastroenterol.* **96**, 132–137 (2001).
55. Montoro-Huguet, M. A., Santolaria-Piedrafita, S., Cañamares-Orbis, P. & García-Erce, J. A. Iron deficiency in celiac disease: prevalence, health impact, and clinical management. *Nutrients* **13**, 3437 (2021).
56. Abu Daya, H., Lebwohl, B., Lewis, S. K. & Green, P. H. Celiac disease patients presenting with anemia have more severe disease than those presenting with diarrhea. *Clin. Gastroenterol. Hepatol.* **11**, 1472–1477 (2013).
57. Scricciolo, A. et al. Efficacy of a high-iron dietary intervention in women with celiac disease and iron deficiency without anemia: a clinical trial. *Nutrients* **12**, 2122 (2020).
58. Ballester-Fernández, C., Varela-Moreiras, G., Ubeda, N. & Alonso-Aperte, E. Nutritional status in Spanish adults with celiac disease following a long-term gluten-free diet is similar to non-celiac. *Nutrients* **13**, 1626 (2021).
59. Remes-Troche, J. M. et al. Metabolic effects in patients with celiac disease, patients with nonceliac gluten sensitivity, and asymptomatic controls, after six months of a gluten-free diet. *Rev. Gastroenterol. Mex.* **85**, 109–117 (2020).
60. Agarwal, A. et al. Patients with celiac disease are at high risk of developing metabolic syndrome and fatty liver. *Intest. Res.* **19**, 106–114 (2021).
61. Zanini, B. et al. Impact of gluten-free diet on cardiovascular risk factors. A retrospective analysis in a large cohort of coeliac patients. *Dig. Liver Dis.* **45**, 810–815 (2013).
62. Kabbani, T. A. et al. Patients with celiac disease have a lower prevalence of non-insulin-dependent diabetes mellitus and metabolic syndrome. *Gastroenterology* **144**, 912–917.e1 (2013).
63. Rispo, A. et al. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease. *Liver Int.* **41**, 788–798 (2021).
64. Tortora, R. et al. Metabolic syndrome in patients with coeliac disease on a gluten-free diet. *Aliment. Pharmacol. Ther.* **41**, 352–359 (2015).
65. Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *Hepatology* **78**, 1966–1986 (2023).
66. Reilly, N. R., Lebwohl, B., Hultcrantz, R., Green, P. H. R. & Ludvigsson, J. F. Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease. *J. Hepatol.* **62**, 1405–1411 (2015).
67. Conroy, M., Allen, N., Lacey, B., Soilleux, E. & Littlejohns, T. Association between coeliac disease and cardiovascular disease: prospective analysis of UK Biobank data. *BMJ Med.* **2**, e000371 (2023).
68. Lebwohl, B., Green, P. H. R., Söderling, J., Roelstraete, B. & Ludvigsson, J. F. Association between celiac disease and mortality risk in a Swedish population. *JAMA* **323**, 1277–1285 (2020).
69. Piątek-Guziewicz, A. et al. Oral vitamin E supplementation in reducing nitrosative stress in adults treated for celiac disease. *Pol. Arch. Intern. Med.* **130**, 711–713 (2020).
70. Bascuñán, K. A. et al. Impact of FODMAP content restrictions on the quality of diet for patients with celiac disease on a gluten-free diet. *Nutrients* **11**, 2220 (2019).
71. Hallert, C., Svensson, M., Tholstrup, J. & Hultberg, B. Clinical trial: B vitamins improve health in patients with coeliac disease living on a gluten-free diet. *Aliment. Pharmacol. Ther.* **29**, 811–816 (2009).
72. Ciacci, C. et al. 25-Hydroxyvitamin D, 1,25-dihydroxyvitamin D, and peripheral bone densitometry in adults with celiac disease. *Nutrients* **12**, 929 (2020).
73. Tavakkoli, A., DiGiacomo, D., Green, P. H. & Lebwohl, B. Vitamin D status and concomitant autoimmunity in celiac disease. *J. Clin. Gastroenterol.* **47**, 515–519 (2013).
74. Hallert, C. et al. Evidence of poor vitamin status in coeliac patients on a gluten-free diet for 10 years. *Aliment. Pharmacol. Ther.* **16**, 1333–1339 (2002).
75. Kaur, P., Agarwala, A., Makharia, G., Bhatnagar, S. & Tandon, N. Effect of gluten-free diet on metabolic control and anthropometric parameters in type 1 diabetes with subclinical celiac disease: a randomized controlled trial. *Endocr. Pract.* **26**, 660–667 (2020).
76. Ludvigsson, J. F., Ludvigsson, J., Ekborn, A. & Montgomery, S. M. Celiac disease and risk of subsequent type 1 diabetes: a general population cohort study of children and adolescents. *Diabetes Care* **29**, 2483–2488 (2006).
77. Unalp-Arida, A., Liu, R. & Ruhl, C. E. Nutrient intake differs among persons with celiac disease and gluten-related disorders in the United States. *Sci. Rep.* **12**, 5566 (2022).
78. Rawal, P. et al. Zinc supplementation to patients with celiac disease — is it required? *J. Trop. Pediatr.* **56**, 391–397 (2010).
79. Guengerich, F. P. Cytochrome P-450 3A4: regulation and role in drug metabolism. *Annu. Rev. Pharmacol. Toxicol.* **39**, 1–17 (1999).
80. Wilkinson, G. R. Drug metabolism and variability among patients in drug response. *N. Engl. J. Med.* **352**, 2211–2221 (2005).
81. Chretien, M. L. et al. Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. *BMJ Open.* **10**, e034086 (2020).

Evidence-based guidelines

82. Morón, B. et al. CYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac disease. *Am. J. Gastroenterol.* **108**, 1344–1351 (2013).
83. Leonard, M. M. et al. Evaluating responses to gluten challenge: a randomized, double-blind, 2-dose gluten challenge trial. *Gastroenterology* **160**, 720–733.e8 (2021).
84. Zühlke, S. et al. CD38 expression on gluten-specific T cells is a robust marker of gluten re-exposure in coeliac disease. *United Eur. Gastroenterol. J.* **7**, 1337–1344 (2019).
85. Sarna, V. K. et al. HLA-DQ–gluten tetramer blood test accurately identifies patients with and without celiac disease in absence of gluten consumption. *Gastroenterology* **154**, 886–896.e6 (2018).
86. Moretti, S. et al. Oxidative stress as a biomarker for monitoring treated celiac disease. *Clin. Transl. Gastroenterol.* **9**, 157 (2018).
87. Adriaanse, M. & Leffler, D. A. Serum markers in the clinical management of celiac disease. *Dig. Dis.* **33**, 236–243 (2015).
88. Fernández-Bañares, F. et al. Activated gut-homing CD8⁺ T cells for coeliac disease diagnosis on a gluten-free diet. *BMC Med.* **19**, 237 (2021).
89. López-Palacios, N. et al. Evaluation of T cells in blood after a short gluten challenge for coeliac disease diagnosis. *Dig. Liver Dis.* **50**, 1183–1188 (2018).
90. Rostom, A., Murray, J. A. & Kagnoff, M. F. Medical position statement on celiac disease. *Gastroenterology* **131**, 1977 (2006).
91. NICE Guidance. Coeliac disease: recognition, assessment and management. NICE <https://www.nice.org.uk/guidance/ng20> (2015).
92. See, J. A., Kaukinen, K., Makharia, G. K., Gibson, P. R. & Murray, J. A. Practical insights into gluten-free diets. *Nat. Rev. Gastroenterol. Hepatol.* **12**, 580–591 (2015).
93. Costa, A. F. et al. Gluten immunogenic peptide excretion detects dietary transgressions in treated celiac disease patients. *World J. Gastroenterol.* **25**, 1409–1420 (2019).
94. Fernández-Bañares, F. et al. Persistent villous atrophy in de novo adult patients with celiac disease and strict control of gluten-free diet adherence: a multicenter prospective study (CADER study). *Am. J. Gastroenterol.* **116**, 1036–1043 (2021).
95. Sharkey, L. M. et al. Optimising delivery of care in coeliac disease — comparison of the benefits of repeat biopsy and serological follow-up. *Aliment. Pharmacol. Ther.* **38**, 1278–1291 (2013).
96. Biagi, F. et al. A second duodenal biopsy is necessary in the follow-up of adult coeliac patients. *Ann. Med.* **46**, 430–433 (2014).
97. Atsawarungrangkit, A. et al. Development of the dietitian integrated evaluation tool for gluten-free diets (DIET-GFD). *Nutrition* **78**, 110819 (2020).
98. Gładys, K., Dardzińska, J., Guzek, M., Adrych, K. & Małgorzewicz, S. Celiac dietary adherence test and standardized dietitian evaluation in assessment of adherence to a gluten-free diet in patients with celiac disease. *Nutrients* **12**, 2300 (2020).
99. Leffler, D. A. et al. A prospective comparative study of five measures of gluten-free diet adherence in adults with coeliac disease. *Aliment. Pharmacol. Ther.* **26**, 1227–1235 (2007).
100. Muhammad, H., Reeves, S., Ishaq, S. & Jeanes, Y. Experiences of outpatient clinics and opinions of telehealth by Caucasian and South Asian patients' with celiac disease. *J. Patient Exp.* **8**, 237437352110180 (2021).
101. Caeiro, C., Pragosa, C., Cruz, M. C., Pereira, C. D. & Pereira, S. G. The role of pseudocereals in celiac disease: reducing nutritional deficiencies to improve well-being and health. *J. Nutr. Metab.* **2022**, 1–8 (2022).
102. Lee, A. R., Ng, D. L., Dave, E., Ciaccio, E. J. & Green, P. H. R. The effect of substituting alternative grains in the diet on the nutritional profile of the gluten-free diet. *J. Hum. Nutr. Diet.* **22**, 359–363 (2009).
103. Wild, D., Robins, G. G., Burley, V. J. & Howdle, P. D. Evidence of high sugar intake, and low fibre and mineral intake, in the gluten-free diet. *Aliment. Pharmacol. Ther.* **32**, 573–581 (2010).
104. Babio, N. et al. Patients with celiac disease reported higher consumption of added sugar and total fat than healthy individuals. *J. Pediatr. Gastroenterol. Nutr.* **64**, 63–69 (2017).
105. Thompson, T., Dennis, M., Higgins, L. A., Lee, A. R. & Sharrett, M. K. Gluten-free diet survey: are Americans with coeliac disease consuming recommended amounts of fibre, iron, calcium and grain foods? *J. Hum. Nutr. Diet.* **18**, 163–169 (2005).
106. Barone, M. et al. A comparison of the nutritional status between adult celiac patients on a long-term, strictly gluten-free diet and healthy subjects. *Eur. J. Clin. Nutr.* **70**, 23–27 (2016).
107. Johnston, C. S., Snyder, D. & Smith, C. Commercially available gluten-free pastas elevate postprandial glycemia in comparison to conventional wheat pasta in healthy adults: a double-blind randomized crossover trial. *Food Funct.* **8**, 3139–3144 (2017).
108. Ehteshami, M. et al. The effect of gluten free diet on components of metabolic syndrome: a randomized clinical trial. *Asian Pac. J. Cancer Prev.* **19**, 2979–2984 (2018).
109. Costa, A. & Brito, G. A. P. Anthropometric parameters in celiac disease: a review on the different evaluation methods and disease effects. *J. Nutr. Metab.* **2019**, 1–9 (2019).
110. Levran, N. et al. Obesogenic habits among children and their families in response to initiation of gluten-free diet. *Eur. J. Pediatr.* **177**, 859–866 (2018).
111. Suárez-González, M., Bousoño García, C., Jiménez Treviño, S., Iglesias Cabo, T. & Díaz Martín, J. J. Influence of nutrition education in paediatric celiac disease: impact of the role of the registered dietitian: a prospective, single-arm intervention study. *J. Hum. Nutr. Diet.* **33**, 775–785 (2020).
112. Ma, C. et al. Food insecurity negatively impacts gluten avoidance and nutritional intake in patients with celiac disease. *J. Clin. Gastroenterol.* **56**, 863–868 (2021).
113. Saturni, L., Ferretti, G. & Bacchetti, T. The gluten-free diet: safety and nutritional quality. *Nutrients* **2**, 16–34 (2010).
114. Lionetti, E. et al. Nutritional status, dietary intake, and adherence to the Mediterranean diet of children with celiac disease on a gluten-free diet: a case-control prospective study. *Nutrients* **12**, 143 (2020).
115. Bascuñán, K. A. et al. Mediterranean gluten-free diet: is it a fair bet for the treatment of gluten-related disorders? *Front. Nutr.* **7**, 583981 (2020).
116. Bakaloudi, D. R. et al. Intake and adequacy of the vegan diet. A systematic review of the evidence. *Clin. Nutr.* **40**, 3503–3521 (2021).
117. Paganizza, S., Zanotti, R., D'Odorico, A., Scapolo, P. & Canova, C. Is adherence to a gluten-free diet by adult patients with celiac disease influenced by their knowledge of the gluten content of foods? *Gastroenterol. Nurs.* **42**, 55–64 (2019).
118. Silvester, J. A., Weiten, D., Graff, L. A., Walker, J. R. & Duerksen, D. R. Is it gluten-free? Relationship between self-reported gluten-free diet adherence and knowledge of gluten content of foods. *Nutrition* **32**, 777 (2016).
119. Leffler, D. A. et al. A simple validated gluten-free diet adherence survey for adults with celiac disease. *Clin. Gastroenterol. Hepatol.* **7**, 530–536.e2 (2009).
120. Roma, E. et al. Dietary compliance and life style of children with coeliac disease. *J. Hum. Nutr. Diet.* **23**, 176–182 (2010).
121. Nikniaz, Z., Shirmohammadi, M. & Akbari Namvar, Z. Development and effectiveness assessment of a Persian-language smartphone application for celiac patients: a randomized controlled clinical trial. *Patient Educ. Couns.* **104**, 337–342 (2021).
122. Rajpoot, P. et al. Adherence to gluten-free diet and barriers to adherence in patients with celiac disease. *Indian J. Gastroenterol.* **34**, 380–386 (2015).
123. Meyer, K. G., Fasshauer, M., Nebel, I. T. & Paschke, R. Comparative analysis of conventional training and a computer-based interactive training program for celiac disease patients. *Patient Educ. Couns.* **54**, 353–360 (2004).
124. Silvester, J. A., Weiten, D., Graff, L. A., Walker, J. R. & Duerksen, D. R. Living gluten-free: adherence, knowledge, lifestyle adaptations and feelings towards a gluten-free diet. *J. Hum. Nutr. Diet.* **29**, 374–382 (2016).
125. Biagi, F. et al. A score that verifies adherence to a gluten-free diet: a cross-sectional, multicentre validation in real clinical life. *Br. J. Nutr.* **108**, 1884–1888 (2012).
126. Coto, L., Mendia, I., Sousa, C., Bai, J. C. & Cebolla, A. Determination of gluten immunogenic peptides for the management of the treatment adherence of celiac disease: a systematic review. *World J. Gastroenterol.* **27**, 6306–6321 (2021).
127. Palanski, B. A. et al. An efficient urine peptidomics workflow identifies chemically defined dietary gluten peptides from patients with celiac disease. *Nat. Commun.* **13**, 888 (2022).
128. Moreno, M. D. L. et al. Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing. *Gut* **66**, 250–257 (2017).
129. Comino, I. et al. Monitoring of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces. *Am. J. Clin. Nutr.* **95**, 670–677 (2012).
130. Burger, J. P. W., van Lochem, E. G., Roovers, E. A., Drenth, J. P. H. & Wahab, P. J. Dose-escalating (50–500 mg) gluten administration leads to detectable gluten-immunogenic-peptides in urine of patients with coeliac disease which is unrelated to symptoms, a placebo controlled trial. *Nutrients* **14**, 1771 (2022).
131. Coto, L., Sousa, C. & Cebolla, A. Dynamics and considerations in the determination of the excretion of gluten immunogenic peptides in urine: individual variability at low gluten intake. *Nutrients* **13**, 2624 (2021).
132. Skodje, G. I. et al. Detection of gluten immunogenic peptides and the celiac disease adherence test to monitor gluten-free diet: a pilot study. *Eur. J. Clin. Nutr.* **76**, 902–903 (2022).
133. Roca, M. et al. Analysis of gluten immunogenic peptides in feces to assess adherence to the gluten-free diet in pediatric celiac patients. *Eur. J. Nutr.* **60**, 2131–2140 (2020).
134. Fernández Miaja, M., Díaz Martín, J. J., Jiménez Treviño, S., Suárez González, M. & Bousoño García, C. Study of adherence to the gluten-free diet in coeliac patients. *An. Pediatr.* **94**, 377–384 (2021).
135. Stefanolo, J. P. et al. Real-world gluten exposure in patients with celiac disease on gluten-free diets, determined from gliadin immunogenic peptides in urine and fecal samples. *Clin. Gastroenterol. Hepatol.* **19**, 484–491.e1 (2021).
136. Porcelli, B. et al. Testing for fecal gluten immunogenic peptides: a useful tool to evaluate compliance with gluten-free diet by celiacs. *Ann. Gastroenterol.* **33**, 631 (2020).
137. Porcelli, B. et al. Fecal gluten immunogenic peptides as indicators of dietary compliance in celiac patients. *Minerva Gastroenterol. Dietol.* **66**, 201–207 (2020).
138. Ruiz-Carnicer, A. et al. Negative predictive value of the repeated absence of gluten immunogenic peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-up in celiac disease. *Am. J. Clin. Nutr.* **112**, 1240–1251 (2020).
139. Silvester, J. A. et al. Exposure sources, amounts and time course of gluten ingestion and excretion in patients with coeliac disease on a gluten-free diet. *Aliment. Pharmacol. Ther.* **52**, 1469–1479 (2020).
140. Comino, I. et al. Prospective longitudinal study: use of faecal gluten immunogenic peptides to monitor children diagnosed with coeliac disease during transition to a gluten-free diet. *Aliment. Pharmacol. Ther.* **49**, 1484–1492 (2019).
141. Garzón-Benavides, M. et al. Clinical utility of urinary gluten immunogenic peptides in the follow-up of patients with coeliac disease. *Aliment. Pharmacol. Ther.* **57**, 993–1003 (2023).
142. Monachesi, C. et al. Determination of urinary gluten immunogenic peptides to assess adherence to the gluten-free diet: a randomized, double-blind, controlled study. *Clin. Transl. Gastroenterol.* **12**, e00411 (2021).

Evidence-based guidelines

143. Marsilio, I. et al. Quality-of-life evaluation in coeliac patients on a gluten-free diet. *Nutrients* **12**, 2981 (2020).
144. Al-sunaid, F. F. et al. The influence of a gluten-free diet on health-related quality of life in individuals with celiac disease. *BMC Gastroenterol.* **21**, 330 (2021).
145. Fueyo-Díaz, R. et al. Influence of compliance to diet and self-efficacy expectation on quality of life in patients with celiac disease in Spain. *Nutrients* **12**, 2672 (2020).
146. Fueyo-Díaz, R. et al. The effect of self-efficacy expectations in the adherence to a gluten free diet in celiac disease. *Psychol. Health* **35**, 734–749 (2020).
147. Canova, C. et al. Quality of life and psychological disorders in coeliac disease: a prospective multicentre study. *Nutrients* **13**, 3233 (2021).
148. Barberis, N., Quattropani, M. C. & Cuzzocrea, F. Relationship between motivation, adherence to diet, anxiety symptoms, depression symptoms and quality of life in individuals with celiac disease. *J. Psychosom. Res.* **124**, 109787 (2019).
149. Halmos, E. P. et al. Food knowledge and psychological state predict adherence to a gluten-free diet in a survey of 5310 Australians and New Zealanders with coeliac disease. *Aliment. Pharmacol. Ther.* **48**, 78–86 (2018).
150. Nikniaz, Z., Asghari Jafarabadi, M., Abbasalizad Farhangi, M., Shirmohammadi, M. & Nikniaz, L. Determinants of health-related quality of life in patients with celiac disease: a structural equation modeling. *Health Qual. Life Outcomes* **19**, 204 (2021).
151. Hughey, J. J. et al. Self-reported dietary adherence, disease-specific symptoms, and quality of life are associated with healthcare provider follow-up in celiac disease. *BMC Gastroenterol.* **17**, 156 (2017).
152. Möller, S. P., Apputhurai, P., Tye-Din, J. A. & Knowles, S. R. Quality of life in coeliac disease: relationship between psychosocial processes and quality of life in a sample of 1697 adults living with coeliac disease. *J. Psychosom. Res.* **151**, 110652 (2021).
153. Sainsbury, K. & Mullan, B. Measuring beliefs about gluten free diet adherence in adult coeliac disease using the theory of planned behaviour. *Appetite* **56**, 476–483 (2011).
154. Sainsbury, K., Mullan, B. & Sharpe, L. Reduced quality of life in coeliac disease is more strongly associated with depression than gastrointestinal symptoms. *J. Psychosom. Res.* **75**, 135–141 (2013).
155. Parker, S. et al. Functional gastrointestinal disorders and associated health impairment in individuals with celiac disease. *Clin. Gastroenterol. Hepatol.* **20**, 1315–1325.e4 (2022).
156. Wolf, R. L. et al. Hypervigilance to a gluten-free diet and decreased quality of life in teenagers and adults with celiac disease. *Dig. Dis. Sci.* **63**, 1438–1448 (2018).
157. Dowd, A. J. & Jung, M. E. Self-compassion directly and indirectly predicts dietary adherence and quality of life among adults with celiac disease. *Appetite* **113**, 293–300 (2017).
158. Marchese, A. et al. Quality of life in coeliac patients: Italian validation of a coeliac questionnaire. *Eur. J. Intern. Med.* **24**, 87–91 (2013).
159. Burger, J. P. W., Van Middendorp, H., Drenth, J. P. H., Wahab, P. J. & Evers, A. W. M. How to best measure quality of life in coeliac disease? A validation and comparison of disease-specific and generic quality of life measures. *Eur. J. Gastroenterol. Hepatol.* **31**, 941–947 (2019).
160. Walker-Smith, J. A., Guandalini, S., Schmitz, J., Shmerling, D. H. & Visakorpi, J. K. Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. *Arch. Dis. Child.* **65**, 909 (1990).
161. Bardella, M. T. et al. Coeliac disease: a histological follow-up study. *Histopathology* **50**, 465–471 (2007).
162. Wahab, P. J., Meijer, J. W. R. & Mulder, C. J. J. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. *Am. J. Clin. Pathol.* **118**, 459–463 (2002).
163. Elli, L. et al. Safety of occasional ingestion of gluten in patients with celiac disease: a real-life study. *BMC Med.* **18**, 42 (2020).
164. Sadeghi, A. et al. The value of a biopsy in celiac disease follow up: assessment of the small bowel after 6 and 24 months treatment with a gluten free diet. *Rev. Esp. Enferm. Dig.* **112**, 101–108 (2020).
165. Cronin, O., Flanagan, E. & Dowling, D. Coeliac disease in the modern era: severity of small bowel mucosal injury at diagnosis with analysis of clinical correlates and rate of improvement on a gluten free diet. *World J. Gastrointest. Pharmacol. Ther.* **9**, 55–62 (2018).
166. Mahadev, S. et al. Factors associated with villus atrophy in symptomatic coeliac disease patients on a gluten-free diet. *Aliment. Pharmacol. Ther.* **45**, 1084–1093 (2017).
167. Pekki, H. et al. Predictors and significance of incomplete mucosal recovery in celiac disease after 1 year on a gluten-free diet. *Am. J. Gastroenterol.* **110**, 1078–1085 (2015).
168. Vécsei, E. et al. Follow-up of pediatric celiac disease: value of antibodies in predicting mucosal healing, a prospective cohort study. *BMC Gastroenterol.* **14**, 28 (2014).
169. Vécsei, A. K., Graf, U. B. & Vogelsang, H. Follow-up of adult celiac patients: which noninvasive test reflects mucosal status most reliably? *Endoscopy* **41**, 123–128 (2009).
170. Rostami, K. et al. Roc-king onwards: intraepithelial lymphocyte counts, distribution and role in coeliac disease mucosal interpretation. *Gut* **66**, 2080–2086 (2017).
171. Rostami, K. et al. Gluten induces subtle histological changes in duodenal mucosa of patients with non-coeliac gluten sensitivity: a multicentre study. *Nutrients* **14**, 2487 (2022).
172. Penny, H. A. et al. Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts. *Gut* **70**, 876–883 (2021).
173. Leibold, B. et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. *Ann. Intern. Med.* **159**, 169–175 (2013).
174. Leibold, B. et al. Mucosal healing and mortality in coeliac disease. *Aliment. Pharmacol. Ther.* **37**, 332–339 (2013).
175. Rubio-Tapia, A. et al. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. *Am. J. Gastroenterol.* **105**, 1412–1420 (2010).
176. Tuire, I. et al. Persistent duodenal intraepithelial lymphocytosis despite a long-term strict gluten-free diet in celiac disease. *Am. J. Gastroenterol.* **107**, 1563–1569 (2012).
177. Pekki, H. et al. Performing routine follow-up biopsy 1 year after diagnosis does not affect long-term outcomes in coeliac disease. *Aliment. Pharmacol. Ther.* **45**, 1459–1468 (2017).
178. Hære, P. et al. Long-term mucosal recovery and healing in celiac disease is the rule—not the exception. *Scand. J. Gastroenterol.* **51**, 1439–1446 (2016).
179. Emilsson, L. et al. Mucosal healing and the risk of serious infections in patients with celiac disease. *United Eur. Gastroenterol. J.* **6**, 55 (2018).
180. Leibold, B., Michaëlsson, K., Green, P. H. R. & Ludvigsson, J. F. Persistent mucosal damage and risk of fracture in celiac disease. *J. Clin. Endocrinol. Metab.* **99**, 609 (2014).
181. Leonard, M. M., Cureton, P. & Fasano, A. Indications and use of the gluten contamination elimination diet for patients with non-responsive celiac disease. *Nutrients* **9**, 1129 (2017).
182. Ciacci, C., Cirillo, M., Cavallaro, R. & Mazzacca, G. Long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage. *Digestion* **66**, 178–185 (2002).
183. Hutchinson, J. M., West, N. P., Robins, G. G. & Howdle, P. D. Long-term histological follow-up of people with coeliac disease in a UK teaching hospital. *QJM* **103**, 511–517 (2010).
184. Latorre, M. et al. Endoscopic biopsy technique in the diagnosis of celiac disease: one bite or two? *Gastrointest. Endosc.* **81**, 1228–1233 (2015).
185. Gulati, S. et al. Near-focus narrow-band imaging classification of villous atrophy in suspected celiac disease: development and international validation. *Gastrointest. Endosc.* **94**, 1071–1081 (2021).
186. Robert, M. E. et al. Statement on best practices in the use of pathology as a diagnostic tool for celiac disease: a guide for clinicians and pathologists. *Am. J. Surg. Pathol.* **42**, e44–e58 (2018).
187. Taavela, J. et al. Validation of morphometric analyses of small-intestinal biopsy readouts in celiac disease. *PLoS ONE* **8**, e76163 (2013).
188. Cellier, C. et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. *Lancet* **356**, 203–208 (2000).
189. Cellier, C. et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. *Gastroenterology* **114**, 471–481 (1998).
190. Verbeek, W. H. M. et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. *Clin. Immunol.* **126**, 48–56 (2008).
191. Cheminant, M. et al. Nkp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study. *Gut* **68**, 1396–1405 (2019).
192. van Wanrooij, R. L. J. et al. Optimal strategies to identify aberrant intra-epithelial lymphocytes in refractory coeliac disease. *J. Clin. Immunol.* **34**, 828–835 (2014).
193. Arguelles-Grande, C., Brar, P., Green, P. H. R. & Bhagat, G. Immunohistochemical and T-cell receptor gene rearrangement analyses as predictors of morbidity and mortality in refractory celiac disease. *J. Clin. Gastroenterol.* **47**, 593–601 (2013).
194. Liu, H. et al. Continual monitoring of intraepithelial lymphocyte immunophenotype and clonality is more important than snapshot analysis in the surveillance of refractory coeliac disease. *Gut* **59**, 452–460 (2010).
195. De Mascarel, A. et al. Mucosal intraepithelial T-lymphocytes in refractory celiac disease: a neoplastic population with a variable CD8 phenotype. *Am. J. Surg. Pathol.* **32**, 744–751 (2008).
196. Farstad, I. N. et al. Heterogeneity of intraepithelial lymphocytes in refractory sprue: potential implications of CD30 expression. *Gut* **51**, 372 (2002).
197. Daum, S. et al. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. *Gut* **49**, 804–812 (2001).
198. Bagdi, E., Diss, T. C., Munson, P. & Isaacson, P. G. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. *Blood* **94**, 260–264 (1999).
199. Branchi, F. et al. The combination of clinical parameters and immunophenotyping of intraepithelial lymphocytes allows to assess disease severity in refractory celiac disease. *Dig. Liver Dis.* **54**, 1649–1656 (2022).
200. Celli, R. et al. Clinical insignificance of monoclonal T-cell populations and duodenal intraepithelial T-cell phenotypes in celiac and nonceliac patients. *Am. J. Surg. Pathol.* **43**, 151–160 (2019).
201. Hussein, S. et al. Clonal T cell receptor gene rearrangements in coeliac disease: implications for diagnosing refractory coeliac disease. *J. Clin. Pathol.* **71**, 825–831 (2018).
202. Goerres, M. S. et al. Azathioprine and prednisone combination therapy in refractory coeliac disease. *Aliment. Pharmacol. Ther.* **18**, 487–494 (2003).
203. Murray, J. A. et al. Mucosal atrophy in celiac disease: extent of involvement, correlation with clinical presentation, and response to treatment. *Clin. Gastroenterol. Hepatol.* **6**, 186–193 (2008).
204. Rondonotti, E. et al. Video capsule enteroscopy in the diagnosis of celiac disease: a multicenter study. *Am. J. Gastroenterol.* **102**, 1624–1631 (2007).

Evidence-based guidelines

205. Chetcuti Zammit, S., McAlindon, M. E., Sanders, D. S. & Sidhu, R. Assessment of disease severity on capsule endoscopy in patients with small bowel villous atrophy. *J. Gastroenterol. Hepatol.* **36**, 1015–1021 (2021).
206. El-Matary, W., Huynh, H. & Vandermeer, B. Diagnostic characteristics of given video capsule endoscopy in diagnosis of celiac disease: a meta-analysis. *J. Laparoendosc. Adv. Surg. Tech. A* **19**, 815–820 (2009).
207. Hopper, A. D., Sidhu, R., Hurlstone, D. P., McAlindon, M. E. & Sanders, D. S. Capsule endoscopy: an alternative to duodenal biopsy for the recognition of villous atrophy in coeliac disease? *Dig. Liver Dis.* **39**, 140–145 (2007).
208. Luján-Sanchis, M. et al. Role of capsule endoscopy in suspected celiac disease: a European multi-centre study. *World J. Gastroenterol.* **23**, 703–711 (2017).
209. Petroniene, R. et al. Given capsule endoscopy in celiac disease: evaluation of diagnostic accuracy and interobserver agreement. *Am. J. Gastroenterol.* **100**, 685–694 (2005).
210. Rokkas, T. & Niv, Y. The role of video capsule endoscopy in the diagnosis of celiac disease: a meta-analysis. *Eur. J. Gastroenterol. Hepatol.* **24**, 303–308 (2012).
211. Pennazio, M. et al. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Guideline — Update 2022. *Endoscopy* **55**, 58–95 (2023).
212. Aziz, I. et al. The clinical and phenotypical assessment of seronegative villous atrophy; a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000–2015). *Gut* **66**, 1563–1572 (2017).
213. Kurien, M. et al. Capsule endoscopy in adult celiac disease: a potential role in equivocal cases of celiac disease? *Gastrointest. Endosc.* **77**, 227–232 (2013).
214. Chetcuti Zammit, S., Kurien, M., Sanders, D. S. & Sidhu, R. What is the role of small bowel capsule endoscopy in established coeliac disease? *Clin. Res. Hepatol. Gastroenterol.* **44**, 753–761 (2020).
215. Chetcuti Zammit, S. et al. Use of small-bowel capsule endoscopy in cases of equivocal celiac disease. *Gastrointest. Endosc.* **91**, 1312–1321.e2 (2020).
216. Chetcuti Zammit, S., Sanders, D. S., Cross, S. S. & Sidhu, R. Capsule endoscopy in the management of refractory coeliac disease. *J. Gastrointest. Liver Dis.* **28**, 15–22 (2019).
217. Atlas, D. S., Rubio-Tapia, A., Van Dyke, C. T., Lahr, B. D. & Murray, J. A. Capsule endoscopy in nonresponsive celiac disease. *Gastrointest. Endosc.* **74**, 1315–1322 (2011).
218. Maiden, L., Elliott, T., McLaughlin, S. D. & Ciclitira, P. A blinded pilot comparison of capsule endoscopy and small bowel histology in unresponsive celiac disease. *Dig. Dis. Sci.* **54**, 1280–1283 (2009).
219. Maiden, L., Thjodleifsson, B., Theodors, A., Gonzalez, J. & Bjarnason, I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. *Gastroenterology* **128**, 1172–1178 (2005).
220. Culliford, A., Daly, J., Diamond, B., Rubin, M. & Green, P. H. R. The value of wireless capsule endoscopy in patients with complicated celiac disease. *Gastrointest. Endosc.* **62**, 55–61 (2005).
221. Perez-Cuadrado-Robles, E. et al. Role of capsule endoscopy in alarm features and non-responsive celiac disease: a European multicenter study. *Dig. Endosc.* **30**, 461–466 (2018).
222. Barret, M. et al. Diagnostic yield of capsule endoscopy in refractory celiac disease. *Am. J. Gastroenterol.* **107**, 1546–1553 (2012).
223. Tomba, C. et al. Enteroscopy for the early detection of small bowel tumours in at-risk celiac patients. *Dig. Liver Dis.* **46**, 400–404 (2014).
224. Tomba, C. et al. Celiac disease and double-balloon enteroscopy: what can we achieve?: the experience of 2 European tertiary referral centers. *J. Clin. Gastroenterol.* **50**, 313–317 (2016).
225. Daum, S. et al. Capsule endoscopy in refractory celiac disease. *Endoscopy* **39**, 455–458 (2007).
226. Efthymakis, K., Milano, A., Laterza, F., Serio, M. & Neri, M. Iron deficiency anemia despite effective gluten-free diet in celiac disease: diagnostic role of small bowel capsule endoscopy. *Dig. Liver Dis.* **49**, 412–416 (2017).
227. Lidums, I., Teo, E., Field, J. & Cummins, A. G. Capsule endoscopy: a valuable tool in the follow-up of people with celiac disease on a gluten-free diet. *Clin. Transl. Gastroenterol.* **2**, e4 (2011).
228. Elli, L. et al. Use of enteroscopy for the detection of malignant and premalignant lesions of the small bowel in complicated celiac disease: a meta-analysis. *Gastrointest. Endosc.* **86**, 264–273.e1 (2017).
229. Van Weyenberg, S. J. B. et al. Comparison of MR enteroclysis with video capsule endoscopy in the investigation of small-intestinal disease. *Abdom. Imaging* **38**, 42–51 (2013).
230. Minordi, L. M. et al. Primary neoplasms of the small bowel at CT: a pictorial essay for the clinician. *Eur. Rev. Med. Pharmacol. Sci.* **22**, 598–608 (2018).
231. Hadithi, M. et al. The value of double-balloon enteroscopy in patients with refractory celiac disease. *Am. J. Gastroenterol.* **102**, 987–996 (2007).
232. Gay, G., Delvaux, M. & Fassler, I. Outcome of capsule endoscopy in determining indication and route for push-and-pull enteroscopy. *Endoscopy* **38**, 49–58 (2006).
233. Li, X., Chen, H., Dai, J., Gao, Y. & Ge, Z. Predictive role of capsule endoscopy on the insertion route of double-balloon enteroscopy. *Endoscopy* **41**, 762–766 (2009).
234. Malamut, G. et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. *Gastroenterology* **136**, 81–90 (2009).
235. Woodward, J. Improving outcomes of refractory celiac disease – current and emerging treatment strategies. *Clin. Exp. Gastroenterol.* **9**, 225–236 (2016).
236. Zammit, S. C. et al. Small bowel capsule endoscopy in refractory celiac disease: a luxury or a necessity? *Ann. Gastroenterol.* **34**, 188–195 (2021).
237. Collin, P. et al. Video capsule endoscopy in celiac disease: current clinical practice. *J. Dig. Dis.* **13**, 94–99 (2012).
238. Gan, J. et al. A case for improved assessment of gut permeability: a meta-analysis quantifying the lactulose:mannitol ratio in coeliac and Crohn's disease. *BMC Gastroenterol.* **22**, 16 (2022).
239. Tveit, K. et al. Intestinal malabsorption of D-xylose: comparison of test modalities in patients with celiac disease. *Scand. J. Gastroenterol.* **45**, 1289–1294 (2010).
240. Corazza, G. R., Di Stefano, M., Mauriello, E. & Bai, J. C. Bones in coeliac disease: diagnosis and treatment. *Best Pract. Res. Clin. Gastroenterol.* **19**, 453–465 (2005).
241. Zanchetta, M. B., Longobardi, V. & Bai, J. C. Bone and celiac disease. *Curr. Osteoporos. Rep.* **14**, 43–48 (2016).
242. Caraceni, M. P. et al. Bone and mineral metabolism in adult celiac disease. *Am. J. Gastroenterol.* **83**, 274–277 (1988).
243. Mazure, R. et al. Bone mineral affection in asymptomatic adult patients with celiac disease. *Am. J. Gastroenterol.* **89**, 2130–2134 (1994).
244. Sugai, E. et al. Bone-specific antibodies in sera from patients with celiac disease: characterization and implications in osteoporosis. *J. Clin. Immunol.* **22**, 353–362 (2002).
245. D'Amelio, P. & Sassi, F. Gut microbiota, immune system, and bone. *Calcif. Tissue Int.* **102**, 415–425 (2017).
246. Fornari, C. M. et al. Pre- and post-treatment serum levels of cytokines IL-1β, IL-6, and IL-1 receptor antagonist in celiac disease. Are they related to the associated osteopenia? *Am. J. Gastroenterol.* **93**, 413–418 (1998).
247. Moreno, M. L. et al. The IL-1 gene family and bone involvement in celiac disease. *Immunogenetics* **57**, 618–620 (2005).
248. Olmos, M. et al. Systematic review and meta-analysis of observational studies on the prevalence of fractures in coeliac disease. *Dig. Liver Dis.* **40**, 46–53 (2008).
249. Heikkilä, K., Pearce, J., Mäki, M. & Kaukinen, K. Celiac disease and bone fractures: a systematic review and meta-analysis. *J. Clin. Endocrinol. Metab.* **100**, 25–34 (2015).
250. Sánchez, M. I. P. et al. Risk of fracture in celiac disease: gender, dietary compliance, or both? *World J. Gastroenterol.* **17**, 3035 (2011).
251. Kamycheva, E., Goto, T. & Camargo, C. A. Celiac disease is associated with reduced bone mineral density and increased FRAX scores in the US National Health and Nutrition Examination Survey. *Osteoporos. Int.* **28**, 781–790 (2017).
252. Zanchetta, M. B. et al. Significant bone microarchitecture impairment in premenopausal women with active celiac disease. *Bone* **76**, 149–157 (2015).
253. Mautalen, C. et al. Effect of treatment on bone mass, mineral metabolism, and body composition in untreated celiac disease patients. *Am. J. Gastroenterol.* **92**, 313–318 (1997).
254. Ferretti, J. et al. Analysis of the structure and strength of bones in celiac disease patients. *Am. J. Gastroenterol.* **98**, 382–390 (2003).
255. Passananti, V. et al. Bone mass in women with celiac disease: role of exercise and gluten-free diet. *Dig. Liver Dis.* **44**, 379–383 (2012).
256. Chin, K.-Y. et al. A mini review on osteoporosis: from biology to pharmacological management of bone loss. *J. Clin. Med.* **11**, 6434 (2022).
257. Kanis, J. A., Cooper, C., Rizzoli, R. & Reginster, J.-Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos. Int.* **30**, 3–44 (2019).
258. Camacho, P. M. et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2020 update. *Endocr. Pract.* **26** (Suppl. 1), 1–46 (2020).
259. Elli, L. et al. Histological evaluation of duodenal biopsies from coeliac patients: the need for different grading criteria during follow-up. *BMC Gastroenterology* **15**, 133 (2015).
260. Kurien, M., Mooney, P. D., Cross, S. S. & Sanders, D. S. Bulb biopsy in adult celiac disease: pros outweigh the cons? *Am. J. Gastroenterol.* **111**, 1205–1206 (2016).
261. Costantino, A. et al. Nutritional and gastroenterological monitoring of patients with celiac disease during COVID-19 pandemic: the emerging role of telemedicine and point-of-care gluten detection tests. *Front. Nutr.* **8**, 622514 (2021).

Acknowledgements

This study was partially funded by the Italian Ministry of Health, Current Research IRCCS. A.C. was excluded from voting on GIP recommendations.

Author contributions

L.E., C. Cellier, B.L., C. Ciacci, M.S., K.E.A.L., S.C.Z., R.S., L.R., J.C.B., A.R.L., M.D., M.E.R., K.R., S.K., I.C., A.C., F.B., J.P.S., R.W., N.T., F.Z., L. Scaramella and S.B.-G. researched data for the article. E.F.V., L.E., D.L., C. Cellier, B.L., C. Ciacci, M.S., K.E.A.L., R.S., J.C.B., L. Scudeller and D.S.S. contributed substantially to discussion of the content. L.E., D.L. and D.S.S. wrote the article. E.F.V., L.E., D.L. and D.S.S. reviewed and/or edited the manuscript before submission.

Competing interests

D.L. receives a salary from Takeda Pharmaceuticals and is on the executive committee of the Foundation for Celiac Disease Outcome Measures. A.C. is a CEO and shareholder of Biomedal SL. The other authors declare no competing interests.

Informed consent

The authors affirm that patient participants provided informed consent for their experiences.

Evidence-based guidelines

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41575-023-00872-2>.

Peer review information *Nature Reviews Gastroenterology & Hepatology* thanks Abdulbaqi Al-Toma, Gemma Castillejo and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Related links

GRADEpro: <https://www.gradepro.org/>

© Springer Nature Limited 2023

¹Center for Prevention and Diagnosis of Celiac Disease-Gastroenterology and Endoscopy Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. ²Celiac Center, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, MA, USA. ³Department of Gastroenterology and Endoscopy, CELAC network, AP-HP Centre, Hôpital Européen Georges Pompidou, Université de Paris, Cité and Institut National du Cancer, Paris, France. ⁴Celiac Disease Center, Department of Medicine, Columbia University Irving Medical Center, Columbia University, New York, NY, USA. ⁵Center for Celiac Disease, Gastrointestinal Unit, AOU San Giovanni di Dio e Ruggi D'Aragona and Department of Medicine Surgery Dentistry, Scuola Medica Salernitana, University of Salerno, Salerno, Italy. ⁶Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Berlin, Germany. ⁷K.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway. ⁸Department of Gastroenterology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. ⁹Department of Medicine, Division of Gastroenterology, Mater Dei Hospital, Msida, Malta. ¹⁰Department of Infection, Immunity and Cardiovascular Diseases, Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK. ¹¹Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy. ¹²Department of Medicine, Dr. C. Bonorino Udaondo Gastroenterology Hospital, Buenos Aires, Argentina. ¹³Department of Pathology and Medicine, Yale University School of Medicine, New Haven, CT, USA. ¹⁴Department of Gastroenterology, Palmerston North District Health Board (DHB), Palmerston North, New Zealand. ¹⁵Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, Seville, Spain. ¹⁶Biomedal S.L., Seville, Spain. ¹⁷Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada. ¹⁸Program in Nutrition, Department of Health Studies & Applied Educational Psychology, Teachers College, Columbia University, New York, NY, USA. ¹⁹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. ²⁰Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy. ²¹Gastroenterology Unit, Azienda Ospedale-Università Padova, Padua, Italy.